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ABSTRACT 
 
BEVERLY M. KNIGHT: INTERPLAY BETWEEN P-GLYCOPROTEIN EFFLUX AND 
CYTOCHROME P4503A-MEDIATED METABOLISM IN INTESTINE 
 
(Under the direction of Dhiren R. Thakker, Ph.D.) 
 
 
Intestinal metabolism and drug efflux are recognized as two important barriers to 
drug absorption.  The interactions between these factors may also be an important 
consideration in evaluating the drug-drug interaction potential of a given compound.  
Presented here are mechanistic studies that examine the interaction between the 
most germane metabolic enzyme/efflux transporter pair: cytochrome P4503A 
(CYP3A) and P-glycoprotein (P-gp).   
 
In order to study this interaction, two model systems and two dual CYP3A/P-gp 
substrates were selected.  The first model used was the CYP3A-expressing Caco-2 
cell system.  This system allowed for detailed mechanistic studies, with few 
confounding factors.  The second system utilized was fresh mouse intestine (from P-
gp competent and deficient mice) in a side-by-side diffusion chamber model.  This 
model provided more physiologically relevant results with the caveat of increased 
complexity.  The two drugs selected for study were terfenadine (an antihistamine) 
and loperamide (an antidiarrheal).  In order to study the interplay between P-gp 
efflux and metabolism, the metabolism of each compound was measured during 
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absorptive transport across Caco-2 cell monolayers and mouse tissue, in the 
presence or absence of P-gp activity. 
 
In the Caco-2 cell system, the results varied between the two compounds.  
Loperamide showed an increase in metabolism in the presence of the P-gp inhibitor 
GW918, while terfenadine showed no change.  The lack of effect for terfenadine 
may be due to the action of a second transporter.  In the mouse intestine, both 
compounds showed a higher metabolic rate in the absence of P-gp expression.  For 
both systems, the effects were seen only within the low dose range, below about 50 
µM.  This study also showed that terfenadine is metabolized about 60% by an 
enzyme that is inhibitable by quinidine (possibly CYP2D22) and only 40% by CYP3A 
in mouse intestine. 
 
The results presented in this dissertation indicate that P-gp efflux effectively 
decreases metabolism in intestine by decreasing intracellular concentrations.  This 
conclusion is also supported by the pharmacokinetic modeling and simulations 
presented.  The mechanistic information collected can provide insight into the nature 
of the CYP3A/P-gp interaction and can help in developing better models to predict in 
vivo intestinal drug-drug interactions.  
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A. ABSTRACT 
 
Metabolism by Cytochrome P4503A (CYP3A) and P-glycoprotein-mediated efflux 
transport are two important biochemical barriers to drug absorption from the 
intestine.  CYP3A, the most abundant subfamily of drug-metabolizing enzymes, 
shares many substrates with the efflux transporter P-glycoprotein (P-gp).  While the 
impact of each of these systems on drug disposition is routinely assessed 
individually, the effect of both systems acting in concert during intestinal absorption 
is difficult to ascertain.  Researchers have published conflicting findings on how 
efflux affects metabolism.  Pharmacokinetic theory predicts that the effect of efflux 
on overall metabolism depends on substrate concentrations relative to the 
respective kinetic parameters of these processes (i.e. affinities for transport and 
metabolism as well as capacities of these processes).  In contrast, the in vitro 
parameters (e.g. extraction ratio, ER) that have been used to explain or predict the 
effect of P-gp-mediated efflux on CYP3A-mediated metabolism of dual substrates 
are more relevant for describing overall changes to extraction efficiency of the 
system (intestinal epithelium), rather than deconvoluting the effect of P-gp on 
CYP3A-mediated metabolism.  Developing a more refined way to understand this 
interplay and its potential relevance to drug absorption is an important goal, as a 
large proportion of marketed drugs and many modern drug discovery candidates are 
known to be affected by one or both of these proteins. Also, since many modern 
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drug discovery candidates are substrates for these processes, a more detailed 
understanding of how these barriers can ultimately influence oral absorption is 
needed for better decision-making for compound progression. 
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B. ORAL DRUG ABSORPTION 
 
The oral route is the preferred route of delivery for most therapeutic agents.  
Despite this, there are still some gaps in our understanding of the mechanisms 
involved in oral absorption.  There are many physical and biochemical factors 
associated with the liver and intestine that can introduce variability in the extent of 
drug absorption.  Further study is, therefore, needed in order to more accurately 
predict the absorptive properties of new drug candidates. 
 
B.1. Intestinal Epithelium 
 
During absorption, drugs must traverse the intestinal epithelium.  The intestinal 
epithelium is a highly specialized barrier that is composed of a continuous single 
layer of polarized cells, or enterocytes (Figure 1.1).  The epithelium is folded into villi, 
which provide a large surface area for absorption of nutrients; the enterocytes also 
have microvilli on the apical (lumenal) side to maximize surface area.  The spaces 
between the cells are bridged by tight junctions, which limit the paracellular 
permeability of most compounds, except those that are very small and hydrophilic.  
Therefore, most compounds are absorbed transcellularly by first crossing the apical 
membrane of the enterocyte by either diffusing passively or by transport using  
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carrier proteins.  Then the compound must diffuse through the cell and cross the 
basolateral membrane (actively or passively) to be absorbed into the bloodstream.  
 
B.2. Bioavailability 
 
Optimization of drug bioavailability is an important aspect of oral delivery of 
human therapeutic agents.  Bioavailability is defined as the rate and extent of drug 
absorption into the systemic circulation (Gilbaldi and Perrier, 1982). Ideally, the 
bioavailability of a therapeutic agent should be high, with low intersubject variability; 
this would help to ensure predictable safety and efficacy.  During drug discovery, a 
great deal of emphasis is placed on improving intestinal absorption by optimizing 
drugs’ physicochemical properties; however, many biological factors can also 
significantly influence a therapeutic agent’s oral bioavailability, including intestinal 
permeability, lumenal contents/pH, GI motility and metabolism by enzymes in the 
intestine.   
 
In order to predict which drugs will be affected by these factors, a model termed 
the Biopharmaceutics Classification System (BCS) has been developed (Amidon et 
al., 1995).  Drugs were placed into four classes based on solubility and permeability 
values (Table 1.1). For the compounds in BCS Class I, the high solubility results in 
saturation of drug efflux and metabolism, so these drugs are likely to have high 
bioavailability values that correlate well with in vitro predictions from dissolution data.  
The compounds in BCS Classes II and III are likely to be substrates for transporters 
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and metabolic enzymes.  For example, many substrates of P-gp are lipophilic and 
therefore fall into Class II: they have high permeability and low aqueous solubility 
(Seelig, 1998).  Thus, the bioavailability of these Class II and III drugs may be 
difficult to predict using physicochemical analyses (Wu and Benet, 2005).  Class IV 
contains drugs with undesirable properties for oral delivery, and therefore relatively 
few drugs from this class have been developed into orally administered products.  
The following discussion will primarily be relevant to the compounds in Classes II 
and III; i.e., the drugs for which current models are unable to accurately predict the 
absorptive behavior. 
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C. BIOCHEMICAL BARRIERS TO DRUG ABSORPTION 
 
In addition to the physicochemical parameters that determine the rate at which a 
compound crosses the epithelium, many biochemical processes can affect the rate 
of absorption and the amount of compound that reaches the portal vein.  For most 
drugs, a primary factor of concern is “first pass” extraction of drugs by metabolism in 
the intestine and liver and biliary excretion in the liver.  Both the liver and intestine 
are rich in drug-metabolizing enzymes, including peptidases, hydrolases, alkaline 
phosphatases, and CYP enzymes.  In addition, uptake transporters in the intestinal 
epithelium such as OATP and PEPT1 can facilitate absorption of compounds, while 
efflux transporters such as P-glycoprotein (P-gp), multidrug resistance associated 
proteins (MRPs) and breast cancer resistance protein (BCRP) can play a role in 
reducing the bioavailability and pharmacokinetic profiles of substrates. 
 
As substrates translocate from the apical side (facing the intestinal lumen) of the 
cells to the basolateral (blood) side, efflux transporters (e.g., P-gp) in the apical 
membrane function to prevent the drug from entering enterocytes, resulting in an 
effective reduction of the compound’s permeability; if this barrier is overcome, the 
drug can then be subject to oxidative metabolism by enzymes, most notably, 
CYP3A, within the smooth endoplasmic reticulum of the enterocyte.  Any drug within 
the enterocyte that is not metabolized or effluxed can diffuse across the basolateral 
membrane and enter the bloodstream, where it is subsequently carried to the liver 
for processing.   
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It is also worth noting that, if solubility is high, a drug may be able to overcome 
the barriers of metabolism and efflux, since both processes are saturable; this may 
be more likely to occur in the proximal intestine, where drug concentrations are often 
higher.  Ultimately, drug bioavailability depends on physical properties of the 
compound and on both hepatic and intestinal first-pass clearance mechanisms.  
 
C.1. Intestinal CYP3A 
 
CYP3A is the most highly expressed subfamily of CYP enzymes in both human 
small intestine and liver (Paine et al., 1997; Paine et al., 2006; Shimada et al., 1994).  
CYP3A enzymes are NADPH-dependent hemoproteins with a wide range of 
substrates, which tend to be relatively lipophilic (Bu, 2006).  Although bound to the 
membranes of endoplasmic reticulum, CYP3A enzymes are in close proximity to the 
apical membrane of enterocytes (Figure 1.4) where P-gp resides (Cummins et al., 
2001).  CYP3A enzymes are involved in the metabolism of a majority of the drugs 
that are on the market and have most frequently been implicated in drug-drug 
interactions (Dresser et al., 2000).  Drugs such as ketoconazole, erythromycin and 
clarithromycin are well known inhibitors of CYP3A that increase the plasma 
concentrations of coadministered CYP3A substrates to toxic levels.  Although in vitro 
assays are often used during drug development in an effort to identify these types of 
interactions for a given compound, the reliability of these predictions is still 
somewhat limited (Obach et al., 2006). 
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CYP3A acts similarly in the intestine and liver (Watkins, 1997), but the average 
intestinal content of CYP3A has been estimated to be only 70 nmoles in humans, 
much less than the average hepatic content of 5000 nmoles (Paine et al., 1997).  
Nevertheless, for certain drugs, intestinal metabolism is at least as extensive as 
hepatic metabolism.  This phenomenon may be explained by better access to the 
enzymes in intestine because of the large absorptive surface area, and also could 
be due to reduced access to hepatic enzymes because of potential binding to 
proteins in portal blood (Hall et al., 1999).  
 
One group of researchers was able to show, using an intestinal perfusion 
technique in humans, an equivalent extent of metabolism of the CYP3A substrate 
verapamil in the intestine and liver (extraction ratios were 0.49 and 0.48, 
respectively) (von Richter et al., 2001).  Other investigators have taken a more direct 
approach. For example, in an experiment conducted during liver transplant surgery, 
it was demonstrated that 43% of an intraduodenal midazolam dose was metabolized 
by intestinal CYP3A during the anhepatic phase of the surgery (Paine et al., 1996).  
These studies demonstrate the importance of intestinal metabolism as well as the 
complexities involved in studying this process clinically.  In addition, intestinal 
CYP3A content varies between patients and is susceptible to inhibition and/or 
induction by co-administered drugs, which may lead to toxicity or a lack of efficacy; 
therefore, understanding the true role of drug metabolism in determining gut 
bioavailability is essential (Lampen et al., 1996).  Unfortunately, there are currently 
few robust methods for determining this contribution.    
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C.2. Intestinal P-glycoprotein (P-gp) 
 
The drug transporting protein P-gp (ABCB1) was first discovered as an efflux 
pump that is highly expressed in multidrug-resistant cells, conferring the MDR 
phenotype (Juliano and Ling, 1976).  Two members of the MDR gene family have 
been identified in humans.  The MDR3 gene encodes a phospholipid “flippase”, 
while the MDR1 gene encodes the better known drug efflux transporter P-gp (van 
Helvoort et al., 1996).   This 170 kDa protein consists of 12 membrane-spanning 
domains and two ATPase catalytic sites that drive drug efflux.  The substrate binding 
site(s) of the protein are thought to be located within the plasma membrane 
(Gottesman and Pastan, 1993), since most P-gp substrates are lipophilic in nature, 
but the mechanism of drug efflux is still under debate.  A “vacuum cleaner” model 
has been proposed by which P-gp siphons drug out of the membrane and extrudes it 
into the extracellular space (Raviv et al., 1990).   
 
Another possible mechanism is the “flippase” model, which theorizes that P-gp 
flips the drug from the inner to the outer leaflet of the membrane (Higgins and 
Gottesman, 1992).  This is plausible since P-gp has been shown to interact with a 
broad range of membrane lipids (van Helvoort et al., 1996; Romsicki and Sharom, 
1999) and since drug efflux can be modulated by various agents which perturb the 
membrane (e.g., PEGs (Shen et al., 2006)). 
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P-gp is now known to be constitutively expressed in many cells of the body 
including hepatocytes, epithelial cells of the placenta and kidney, the capillary 
endothelium that comprises the blood-brain barrier, and the columnar cells of 
intestinal epithelium.  It plays a protective role in many tissues, including the small 
intestine.  P-gp resides in the apical membranes of intestinal enterocytes (Thiebaut 
et al., 1987), where it modulates apical to basolateral (luminal to blood) permeability 
by effluxing compounds from enterocytes back into the intestinal lumen.  It should be 
noted that this is opposite to the direction of flux in the liver, where drugs enter 
hepatocytes from the portal blood across the basolateral (sinusoidal) membrane and 
can be metabolized within the cell or pumped into bile by efflux transporters at the 
apical (canalicular) membrane (Figure 1.1).  Consequently, the role of P-gp differs in 
these two organs: in the liver, it can act as a clearance mechanism competing with 
metabolism, while in intestine it can reduce the rate and extent of absorption.   
 
The effect of P-gp on drug absorption has been clearly established in mice 
deficient for the P-gp gene(s) (Smit et al., 1998).  In addition, a subpopulation of 
collie dogs deficient in functional P-gp has been shown to exhibit toxicity after oral 
ingestion of the antiparasitic drug, ivermectin (Paul et al., 1987) (Roulet et al., 2003).  
A growing body of evidence supports the importance of P-gp in intestinal drug-drug 
interactions (Endres et al., 2006).  For example, rifampin has been shown to induce 
P-gp in the intestine, decreasing the area under the curve (AUC) of orally dosed 
digoxin, in healthy volunteers (Achira et al., 1999).  Another clinical study found a 
significant inverse correlation between intestinal P-gp expression and cyclosporine A 
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maximum plasma concentration (Cmax) in 25 renal transplant patients (Lown et al., 
1997).  A third clinical study concluded that an interaction between rifampin and oral 
erythromycin was most likely caused by P-gp induction (Paine et al., 2002).  In rats, 
ketoconazole was shown to increase digoxin AUC approximately 5-fold after oral 
dosing by inhibiting intestinal P-gp (Salphati and Benet, 1998).  Studies comparing 
P-gp-deficient mice to normal mice have also shown increases in drug bioavailability 
and systemic exposure of P-gp substrates in the absence of P-gp expression (Chen 
et al., 2003). It is probable that many drug-drug interactions that were previously 
attributed to CYP3A are at least in part due to the activity of intestinal P-gp, as was 
shown previously for cyclosporine A (Lown et al., 1997). 
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D. METABOLISM/TRANSPORTER INTERPLAY 
 
Some investigators have considered the possibility of functional interplay 
between drug transporters and metabolic enzymes in the intestine and its effect on 
drugs that are substrates for both proteins (Cummins et al., 2002).  Although there 
are many efflux transporters and metabolic enzymes that can affect drug absorption, 
most studies in this area have focused on the interaction between P-gp and CYP3A 
due to their wide and overlapping substrate specificities (Table 1.2), co-localization, 
and similarity of (protective) function.   
 
In addition to location, P-gp and CYP3A have overlapping, yet not identical, 
regulatory pathways (Schuetz et al., 1996) and, as mentioned above, share many of 
the same substrates (Table 1.2).  These observations have led to the hypothesis 
that transport and metabolic processes work cooperatively to reduce absorption of 
dual substrates across the enterocyte layer.  However, the literature is not quite 
unified on how these two proteins interact with each other to attenuate the oral 
bioavailability of their dual substrates.   
 
This type of functional interaction is not without precedent.  P-gp activity has 
previously been shown to decrease metabolism of dual substrates in the liver.  In a 
previous study, P-gp deficient mice (mdr1a/1b(–/–)) and mice expressing P-gp 
(mdr1a/1b(+/+)) were compared with regards to erythromycin metabolism by hepatic 
CYP3A.  The assay utilized, the erythromycin breath test, has been considered to be 
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primarily a measure of hepatic CYP3A metabolism. Although the two strains of mice 
showed equivalent levels of CYP3A expression, and equivalent CYP3A activity in 
liver microsomes, the deficient mice showed about a 2-fold higher AUC (area under 
the curve) and increased maximum 14CO2 exhalation rate (a measure of hepatic 
CYP3A activity) (Lan et al., 2000), suggesting that P-gp efflux can attenuate hepatic 
CYP3A metabolism.  However some recent evidence has suggested that the 
erythromycin breath test may also reflect P-gp activity (Kurnik et al., 2006).  The 
authors showed that the P-gp inhibitor taquidar could increase the 14CO2 exhalation 
rate, independent of CYP3A activity.  Therefore, the results from this study may 
need to be reassessed in light of the recent reports of the effect of P-gp on this 
assay.   
 
The first group to study the P-gp/CYPA interaction in vitro noted that oxidative 
metabolism of the dual substrate cyclosporine A was greater during absorptive 
transport (apical to basolateral) than during secretory transport (basolateral to 
apical) across Caco-2 cell monolayers (an immortalized human colon carcinoma cell 
line used as an in vitro model of human intestinal epithelium), implying an 
enhancement of metabolism in the absorptive direction due to P-gp efflux.  These 
authors proposed that extension of cellular transit time was the underlying 
mechanism by which the efflux activity of P-gp at the apical membrane could 
influence metabolism (Gan et al., 1996).  Subsequently, several studies have been 
performed to investigate the mechanism of this interaction, leading to the hypothesis 
that transport and metabolic processes, catalyzed by P-gp and CYP3A respectively, 
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work cooperatively to reduce absorption of dual substrates across intestinal 
epithelium (Gan et al., 1996; Hochman et al., 2000; Cummins et al., 2001; Cummins 
et al., 2002; Benet et al., 2004).  
 
 
D.1. Current In Vitro Approaches for Understanding CYP3A/P-gp Interplay 
 
There are a few in vitro methods that have been used to elucidate the 
interactions between P-gp and CYP3A, in attempts to clarify their combined effect on 
the intestinal absorption of dual substrates.  The Caco-2 cell model (Figure 1.2) is 
used to study drug transport due to its morphological and biochemical similarity to 
the intestinal epithelium, including expression of P-gp.  Unlike enterocytes, quiescent 
Caco-2 cells do not normally express CYP3A4.  However, methods have been 
adapted to allow study of both transport and metabolism either by transfection with 
the CYP3A gene or by treating cells with 1α, 25-dihydroxyvitamin D3, which induces 
functionally active CYP3A (Schmiedlin-Ren et al., 1997).  For compounds that are 
dual CYP3A/P-gp substrates, the interaction between transport and metabolism is 
often assessed by comparing the extent of metabolism relative to drug transported, 
in the presence versus absence of a P-gp inhibitor.  However, there is still some 
uncertainty as to which parameters should be used in interpreting the results of 
these studies.  Hochman, et al. used the following equation to calculate the extent of 
metabolism in cell transport studies (Hochman et al., 2000): 
out
smetabolite
M
M
 / ∑=ratioparentMetabolite      Equation 1  
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where Mmetabolites is the cumulative mass of all metabolites from all compartments 
at time t and Mout is the mass of parent compound appearing in the receiver 
compartment at time t. 
 
Another parameter, the extraction ratio (ER), has been proposed by Fisher et al. 
(Fisher et al., 1999): 
   
∑
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Subsequently, Benet et al. (Benet et al., 2004) modified this definition to include 
the amount of intracellular parent drug (Mparent) in the denominator of the above 
equation to produce equation 3:   
 
∑
∑
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ER          Equation 3 
 
We feel that this approach of defining ER is not valid because intracellular 
parent, as defined in equation 3, is not committed to metabolism and/or egress into 
the basolateral compartment; rather, a fraction is available for efflux back into the 
apical compartment.   
 
It should be noted that these equations attempt to quantify the efficiency of the 
cell monolayer in removing the parent drug and to provide a relationship between 
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how much parent drug is metabolized vs. how much ultimately reaches the receiver 
compartment intact.  However, these relationships have also been used to explain 
how P-gp efflux affects metabolism.  That is, a decrease in ER with P-gp inhibition 
presumes a decrease in metabolism, implying that active P-gp increases 
metabolism.  For example, Cummins et al. (Cummins et al., 2002) used the CYP3A-
expressing Caco-2 cell model to show that the ER (equation 3) of the dual 
CYP3A/P-gp substrate K77, a cysteine protease inhibitor, decreased from 33% to 
14% in the presence of the selective P-gp inhibitor GW918.  The authors concluded 
that P-gp activity enhances the metabolism of K77 by CYP3A using Equation 3, 
which includes intracellular parent in the denominator of the equation.  Measuring 
intracellular concentrations of parent drug in the K77 study, however, did provide an 
insight that was perhaps not intended.  This data showed that intracellular 
concentrations of K77 attained upon inhibition of P-gp (estimated >200 µM) may 
have exceeded the linear range for its CYP3A4-mediated metabolism (based on a 
reported Km of ~14 µM for CYP3A metabolism using human liver microsomes 
(Jacobsen et al., 2000)).   
 
Another Caco-2 cell study, conducted using the dual substrate sirolimus, yielded 
similar conclusions (Cummins et al., 2004), but the results of this study were also 
confounded by the inhibitory nature of metabolites of sirolimus.  A subsequent K77 
study utilizing the perfused rat intestine model also showed a slight decrease in the 
ER with GW918 treatment but this difference was not significant (Cummins et al., 
2003).  Another research group corroborated the results by showing that inhibition of 
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P-gp in CYP3A4-competent Caco-2 cells increased the extraction ratio of indinavir in 
the A-to-B direction, although the extent of metabolism was unchanged (Hochman et 
al., 2000) (Hochman et al., 2001); interestingly, cyclosporine A was used as a 
specific P-gp inhibitor in this study, although it has been used as a CYP3A inhibitor 
by the previous investigators at the same concentration.  In addition, a theoretical 
model developed by Ito et al. showed that this synergistic effect is enhanced when 
the diffusion rate of the drug through the cytoplasm is slow (Ito et al., 1999).   
 
D.2. Mathematical Models for Studying CYP3A/P-gp Interplay 
 
Based on their results, Benet et al. proposed a mechanism by which a drug 
undergoes perpetual cycles of diffusion into and efflux out of the enterocytes as it 
travels down the intestine, increasing metabolic enzyme exposure, and therefore 
increasing the extent of metabolism by prolonging the mean residence time (MRT) of 
drug in the intestine and at the enzyme site (Benet et al., 2004).  A pharmacokinetic 
model was specifically developed to examine this possibility (Tam et al., 2003a); it 
showed that secretion could increase metabolite formation only under narrowly 
defined conditions: metabolism must be saturable, apical absorption must be fairly 
rapid, and drug partitioning at the basolateral compartment must be low.  For all 
other scenarios tested, efflux increased MRT in all compartments but failed to elicit a 
corresponding increase in metabolite accrual.   
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Several pharmacokinetic models have been developed which have failed to 
predict the experimentally observed decrease in extraction ratio with P-gp inhibition, 
except in the presence of system nonlinearity (Tam et al., 2003a; Tam et al., 2003b) 
i.e., when drug concentrations within the cell are sufficient to saturate or inhibit 
metabolism.  Theoretical work done by one group demonstrated that efflux and 
metabolic clearances are not independent; rather, these processes may compete 
with one another.  Therefore, an increase in intrinsic efflux clearance would be 
expected to result in a decrease in observed metabolic clearance (Tam et al., 2003), 
i.e., under linear metabolic conditions, drug efflux from cell monolayers would be 
expected to decrease, not increase, metabolism.  However, further work from this 
group supported the idea that, under nonlinear metabolic conditions, efflux may be 
able to increase metabolism by decreasing enzyme saturation (Johnson et al., 
2003a).   In other words, P-gp efflux may increase the efficiency of a compound’s 
metabolism by reducing the parent concentration in the cell, and therefore 
maintaining linear conditions.  This may help explain the unexpectedly high intestinal 
metabolism of compounds whose clinically dosed concentrations would be expected 
to produce enzyme saturation.  
 
Another group reached a similar conclusion from experiments that examined the 
transport of verapamil in vitro across rat intestinal mucosa (Ussing chamber) 
(Johnson et al., 2003a), in situ (autoperfused rat jejunum) (Johnson et al., 2003b), 
and through development of compartmental models to describe these processes.  
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Their simulations also showed that, in order for P-gp to increase the extraction ratio, 
nonlinearity must be inherent in the system (Johnson et al., 2003a).   
 
Similarly, a study done with the dual substrate saquinavir in the CYP3A4-
expressing Caco-2 cell system showed that inhibition of P-gp increased the rate of 
metabolism but ER decreased with increasing dose (Table 1.3), implying that the 
intracellular concentrations of saquinavir achieved by P-gp inhibition were likely to 
be in the range to saturate metabolism (Mouly et al., 2004).  These results confirmed 
earlier theoretical work, which predicted that a decrease in extraction ratio with P-gp 
inhibition could occur only in the presence of such a system nonlinearity (Johnson et 
al., 2001; Johnson et al., 2003a; Tam et al., 2003a; Tam et al., 2003b).  While it is 
recognized that saturation is possible for both efflux and metabolic processes, few 
studies have accounted for the effect of this nonlinearity when assessing the P-
gp/CYP3A interaction.   
 
Recently it was shown that P-gp inhibition increased metabolism of the dual 
substrate UK-343,664 in both the perfused rat ileum and jejunum (Kaddoumi et al., 
2006).  The authors had set out to study regional differences in the intestine, which 
are also an important consideration when evaluating the P-gp/CYP3A4 interaction.  
CYP3A is most highly expressed in proximal regions of the intestine (Paine et al., 
1997), while P-gp appears to be more active distally (Stephens et al., 2001), and 
wide interindividual variability is observed for both proteins (Lindell et al., 2003).  
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Some theoretical work has been done to explore the implications of this 
heterogeneity (Tam et al., 2003b).   
 
Of course, mathematical models cannot substitute for experimental data, but the 
lack of agreement between these models and observed results may be indicative of 
a gap in our understanding of these processes.   
 
E. CAN CURRENTLY USED PARAMETERS QUANTIFY THE EFFECT OF EFFLUX ON 
METABOLISM? 
 
Equations 1-3 can be used to quantify changes in the relative amounts of 
metabolites versus parent drug appearing on the basolateral side of the cell 
monolayer, but can they accurately quantify how efflux affects metabolism?  These 
two experimental goals are not the same.  To illustrate this difference, Table 1.3 
shows the reported (or calculated) ER values for several compounds, as well as the 
corresponding values for the percent of applied dose metabolized.  It is clear that the 
changes in percent metabolized with P-gp inhibition are very small compared with 
those reported for ER, and the change can be opposite in direction, leading to 
different conclusions.  In fact, when the amount of metabolites produced is 
unchanged by P-gp inhibition, a decrease in ER is obtained using this equation.  
This can occur because P-gp ultimately influences the amount of parent appearing 
in the receiver compartment, and by definition ER must be affected by P-gp activity, 
irrespective of its effect on metabolism.  Figure 1.3 further illustrates this key point.     
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The primary action of P-gp-mediated efflux is to reduce the permeability of the 
substrate across the enterocyte layer.  Indeed, P-gp-mediated efflux activity will 
reduce the (steady-state) flux of a compound across the cell layer rather than 
prevent it (P-gp in the intestine does not act as a true clearance mechanism).  In this 
regard, P-gp can determine how much of the dose (M0) ultimately enters the cell 
(Min) per given time, under sink conditions.  Min is the total amount of the drug that 
can be irreversibly cleared; it can be expressed as amount of metabolites 
(Mmetabolites) plus the amount of parent drug that reaches the basolateral chamber 
(Mout).  It is important to note that Mmetabolites and Mout represent the amount of the 
parent drug that is no longer subject to metabolic clearance or efflux into the apical 
compartment.  Mout is affected by P-gp and CYP3A, but in different ways: P-gp 
indirectly affects Mout by influencing the magnitude of Min, while CYP3A can directly 
affect Mout because the rate of loss to metabolism of Min competes with the rate of 
appearance of intact drug in the basolateral compartment as Mout.  Due to the 
sensitivity of Mout to both P-gp and CYP3A activity, relationships that include Mout 
cannot clearly quantify how efflux affects metabolism.  Thus ER cannot solely be 
used to quantify how efflux affects metabolism, but it can be used to gauge how 
changes to the system (differences in efflux or metabolism) affect the amount of 
intact drug that crosses the cell monolayer to reach the basolateral compartment.   
 
The definition of ER in equation 2 derives from the following pharmacokinetic 
definition of extraction ratio: 
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where Min is the compound that is available to be cleared and Min – Mout is equal to 
the amount lost to metabolism, i.e. Mmetabolites.  While Mout and Mmetabolites are easy to 
measure, Min cannot be directly measured; therefore, equation 2 can be considered 
an operationally useful form of equation 4.  It is important to note for this type of 
experiment that Min is not the applied dose (M0; see Figure 1.3); rather, it is the 
amount of compound that is available for CYP3A to clear via metabolism or for 
egress into the basolateral compartment.  Again, it is easy to see with Equation 4 
and Figure 1.3 that P-gp’s influence on Min can confound attempts at understanding 
the consequences of changes in P-gp activity on metabolism.   
 
Although the ER seems to derive from the EH (hepatic extraction ratio), there is 
really little resemblance between the two parameters, so conclusions based on ER 
should be carefully considered.  In an in vitro system there are several implicit 
assumptions for use of this parameter: 1.The system is well-stirred and is at steady-
state, so the effect of flow into the cell (permeability x surface area) is ignored.  2. 
Metabolism occurs within the linear range even when P-gp is inhibited.  3. 
Paracellular flux is negligible and transcellular flux is not affected by intracellular 
binding.  4. The amount transported is proportional to the amount metabolized, since 
both values depend on intracellular concentrations.  This last assumption is 
particularly important, since this implies that the extraction ratio should not change 
with changes in intracellular concentrations.  If a decrease in extraction ratio is 
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observed with P-gp inhibition, this indicates that the amount transported increased to 
a greater extent than the amount metabolized, meaning that the assumptions of the 
model have been violated.   
 
Therefore, the ER cannot be used alone as a surrogate for enterocytic clearance 
when comparing metabolic efficiencies in the presence versus absence of P-gp 
efflux, because this violates the assumptions of the model.  The ER appears to be 
more sensitive to changes in efflux than changes in metabolism, i.e. compounds with 
higher AQ value (absorptive quotient, a measure of the functional effect of P-gp in 
the absorptive direction (Troutman and Thakker, 2003)) would be expected to 
produce a more significant change in ER when P-gp is inhibited than those with 
lower AQ values.  Thus the enterocytic metabolic clearance and percent of dose 
metabolized may be more relevant parameters for assessing this interaction.   
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F. CONCLUSIONS 
 
It appears that current in vitro analyses are insufficient for prediction of the 
combined effect of CYP3A and P-gp, since the data cannot easily be extrapolated to 
in vivo findings.  It is currently very difficult to understand the role of CYP3A4 alone 
during drug absorption; our lack of understanding of the CYP3A4/P-gp interplay may 
be partially due to poor understanding of intestinal metabolism and our inability to 
accurately quantify it.  While the Caco-2 cell system represents a valuable model for 
the study of drug absorption, the experimental conditions commonly used for these 
cellular assays are likely to cloud the interaction between P-gp and CYP3A, 
producing misleading conclusions.  Furthermore, the parameters used to quantify 
the purported synergism between the proteins may not be useful for prediction of in 
vivo outcomes.  Unfortunately, it is often difficult to extrapolate from the results 
observed in a reduced in vitro system in which certain factors are ignored to the 
overall complexity of interacting factors seen in vivo.   
 
For drugs that are substrates for both P-gp and CYP3A, a better understanding 
of the mechanisms of interplay between the activities of these two proteins is 
essential to making informed predictions regarding their effect on absorption of these 
compounds.  Clearly the kinetic complexity of this interaction, and the apparent 
disagreement between conclusions derived from experimental versus theoretical 
studies, provide a clear rationale for further mechanistic studies on this subject 
matter.  Indeed, the nature of this interaction can best be understood on a molecular 
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level in its unique context: intestine or liver.  This dissertation asserts that in vitro 
approaches published to date, involving determination of the ER, cannot dissect how 
P-gp affects CYP3A-mediated metabolism from the overall outcome in terms of 
intestinal epithelium- or cell monolayer-mediated extraction.  Furthermore, 
application of pharmacokinetic theory supports using the Fisher definition of ER 
(Fisher et al., 1999) (equation 2) over that proposed by Cummins et al. (Cummins et 
al., 2002) (equation 3) to understand the overall relevance of P-gp/CYP3A interplay.  
Nonetheless, percentage of dose metabolized would represent the most relevant 
parameter for studying this interaction.  However, these studies should be conducted 
over a range of time and intracellular drug concentrations in order to account for 
non-linearity in transport and metabolism when considering the overall effect of the 
interplay of P-gp and CYP3A on drug absorption.  
 
Currently used drug screens can identify drug candidates as P-gp or CYP3A 
substrates, but are unable to address potential interactions between these systems.  
This is primarily due to the lack of information regarding this interaction, and the 
inability to scale in vitro results to in vivo situations.  This information is critical for 
drugs that are substrates for both proteins and have narrow therapeutic indices; a 
better understanding of the mechanisms of interplay between P-gp and CYP3A is 
essential to making informed predictions regarding absorption of these compounds.  
A more thorough examination of the problem is required in order to develop 
predictive models that can be used in drug discovery and development settings. 
 
 27 
G. PROPOSED RESEARCH 
 
      The goal of the studies outlined in this dissertation was to test the hypothesis that 
P-gp efflux decreases the rate of CYP3A-mediated metabolism of dual substrates in 
the intestine in a concentration-dependent manner.  As discussed in this chapter, 
there is some controversy in this area regarding previously reported data and 
especially the interpretation of the data.  This dissertation aimed to examine the 
problem more broadly by studying the metabolism of P-gp/CYP3A substrates over a 
wide concentration range, in the presence and absence of P-gp efflux activity.  
These studies used in vitro models to study the interaction between P-gp and 
CYP3A on a more mechanistic level. 
 
Although some in vitro screens are available to study the properties of new drug 
entities, these systems determine the susceptibility of a molecule to transport and 
metabolic processes separately and therefore cannot be used to study 
transport/metabolism interplay.  An in vitro system that could be used to 
simultaneously study transport and metabolism would have significant advantages 
over existing methodologies.  Therefore, two in vitro systems that provide the 
capability of measuring both transport and metabolism were used to study the P-
gp/CYP3A interaction: Caco-2 cells (an in vitro model derived from human colon 
carcinoma cells) that express both P-glycoprotein (constitutively) and CYP3A4 (by 
induction with 1α, dihydroxyvitamin D3) and fresh mouse intestine from P-gp-
competent and -deficient mice.  The intestinal tissues were used in a side-by-side 
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diffusion chamber in order to measure metabolism during absorptive transport 
across the tissues.  Although this model has been used for some time, it has rarely 
been used for metabolic experiments.  In fact, most of the studies done in this area 
of transport/metabolism interaction have involved cell lines only.  The diffusion 
chamber system is more physiologically relevant than a simple model consisting of 
only one cell type and therefore provides valuable information about the P-
gp/CYP3A interaction.  However, potential species differences must be kept in mind 
when using the mouse model.   Chemical inhibitors were used to modulate P-gp in 
the Caco-2 cell system, while genetic knockout was used for the mouse model.  
Combination of the data from these two systems afforded enhanced interpretive 
power as well as better predictions of clinical scenarios. 
 
For this dissertation, two drugs, loperamide and terfenadine, were chosen to 
study the P-gp/CYP3A interaction.   Since drugs with high permeability and low 
solubility (BCS Class II) are more likely to be affected by metabolism and transport, 
and are therefore more likely to show the interaction between the two processes, 
both drugs were selected from this class.  
 
First, the dual P-gp/CYP3A substrate loperamide was selected for study due to 
its proven affinity for CYP3A (Kim et al., 2004) and its susceptibility to P-gp efflux 
(Wandel et al., 2002).  Loperamide is an opioid derivative that is used as an anti-
diarrheal agent.  Loperamide is poorly absorbed due to high first-pass and 
transporter effects: after an oral dose in humans only 0.3% of the dose was found in 
 29 
the plasma (Heykants et al., 1974).  The extensive first-pass metabolism of 
loperamide made it a good candidate for these experiments, since metabolites were 
readily detectable.  Loperamide has been characterized as a P-gp substrate (Bentz 
et al., 2005).  Central nervous system side effects are uncommon due to the low 
plasma concentrations attained and due to P-gp efflux at the blood-brain barrier.    
Brain uptake clearances of loperamide were reported to be approximately 10-fold 
higher in P-gp-deficient mice than in the wild-type (Dagenais et al., 2004).  
Loperamide has also been shown to alter the disposition of the well-known P-gp 
substrate ivermectin: intestinal secretion of ivermectin was decreased in the 
presence of loperamide, implying competition for the P-gp transporter (Lifschitz et 
al., 2004).  In Caco-2 cell studies, the secretory permeability of loperamide has been 
reported to be 17-fold higher than absorptive permeability (Crowe and Wong, 2004). 
 
Loperamide has two major metabolites, which are formed from subsequent 
demethylation reactions.  The drug is extensively metabolized, which facilitates 
detection of metabolites.   Loperamide has been shown to be metabolized by 
several CYP isoforms in human liver microsomes, particularly by CYP3A4 and 
CYP2C8.  A few drug-drug interactions have been reported for this compound.  One 
study reported an increase in AUC with coadministration of ritonavir (a CYP3A 
inhibitor) (Tayrouz et al., 2001), while another showed that plasma concentrations of 
loperamide were increased by both CYP3A4 inhibitor itraconazole and CYP2C8 
inhibitor gemfibrozil after oral dosing in healthy human volunteers (Niemi et al., 
2006). However, CYP3A appears to be predominately responsible for its 
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metabolism, since 1 µM ketoconazole was shown to inhibit the formation of 
demethyl-loperamide (DLOP) by 90% in human liver microsomes (Kim et al., 2004).   
 
To help determine the parameters that influence the interaction between P-gp 
and CYP3A in the intestine, the dual P-gp/CYP3A substrate terfenadine (Ling et al., 
1995; Raeissi et al., 1999; Polli et al., 2001) was also selected for study.  
Terfenadine is a second-generation (non-sedating) antihistamine prodrug that was 
once widely prescribed but has been removed from the market due to safety 
concerns.  It is known to be extensively metabolized by CYP3A during absorption, 
resulting in a bioavailability of <1% (Raeissi et al., 1999); this high first-pass 
metabolism makes the drug particularly susceptible to drug-drug interactions, since 
inhibition of this enzyme has the potential to increase systemic concentrations of the 
parent drug substantially.  The two main metabolites of terfenadine are fexofenadine 
and azacyclonol.   
 
Terfenadine is also subject to efflux by P-gp, which represents another barrier to 
its absorption from the intestine (Raeissi et al., 1999; Polli et al., 2001).  Therefore, 
terfenadine is likely to be affected by both metabolic and efflux transporter 
processes during absorption.  This makes it a good candidate for studying the 
interplay between P-gp and CYP3A.  However, the extent to which its absorption is 
affected by P-gp is less than that for loperamide.  Therefore, a different extent of 
effect of P-gp on its metabolism was expected. 
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In summary, two in vitro models and two dual P-gp/CYP3A substrates were used 
to study the interaction between P-gp and CYP3A in intestine.  Pharmacokinetic 
modeling was also used in order to make predictions about the behavior of dual 
substrates under differing conditions (i.e., in different regions of the intestine) and 
also to examine the parameters commonly used to assess the P-gp/CYP3A 
interaction.  This combination of approaches allowed prediction of the in vivo 
relevance of the P-gp/CYP3A interaction in intestine. 
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Table 1.1: Biopharmaceutics 
Classification System 
Class I: 
High solubility 
High permeability 
Class II: 
Low solubility 
High permeability 
Class III:  
High solubility 
Low permeability 
Class IV: 
Low solubility 
Low permeability 
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Table 1.2. Proposed P-
gp/CYP3A4 dual substrates 
Amiodarone Nelfinavir
Amprenavir Nicardipine
Atorvastatin Nifedipine
Cephaeline Nitrendipine
Cerivastatin Paclitaxel
Colchicine Pimozide
Cortisol Prednisolone
Cyclosporin A Progesterone
Dexamethasone Quinidine
Diltiazem Quinine
Ebastine Ritonavir
Erythromycin RU486
Etoposide Saquinavir
Felodipine Simvastatin
Indinavir Sirolimus
Itraconazole Tacrolimus
Ketoconazole Tamoxifen
Lidocaine Terfenadine
Loperamide Testosterone
Lopinavir Tirilazad
Lovastatin Verapamil
Methadone Vincristine
Methylprednisolone Vinorelbine
 
 40 
 
 
Table 1.3. Comparison of percent metabolized and ER for CYP3A/P-gp dual 
substrates, with or without treatment with P-gp inhibitors. 
% Metabolized % Metabolized ER ER
(Untreated) (+Inhibitor) (Untreated) (+Inhibitor)
K77 10 2.0% 3.3% 33% 14% 6
Indinavir 5 1.4% 1.8% 24% 17% 8
Saquinavir 10 0.2% 0.7% 22% 10% 15
Saquinavir 20 0.2% 0.6% 10% 6% 15
Saquinavir 40 0.2% 0.3% 6% 3% 15
ReferenceSubstrate Dose (µM)
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Figure 1.1. Barriers to drug absorption in enterocytes (left) and 
hepatocytes (right) 
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Figure 1.2. Schematic of Caco-2 cell 
monolayers grown on Transwell ® inserts.  
Arrow denotes absorptive transport. M0: 
parent dose; Min: total amount of the drug 
that can be irreversibly cleared; Mout: 
amount of parent drug that reaches the 
basolateral chamber; AP: apical; BL: 
basolateral 
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Figure 1.3. Schematic depicting ER parameters. M0: 
parent dose; Min: total amount of the drug that can be 
irreversibly cleared; Mmet: total metabolites produced; 
Mout: amount of parent drug that reaches the 
basolateral chamber; AP: apical; BL: basolateral; ka: 
absorption rate constant  
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Figure 1.4. CYP3A expression in human intestinal mucosa. 
Watkins, P. B. (1997) Adv Drug Deliv Rev 27, 161-170 
 
 CHAPTER 2: METHODS 
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A. CHEMICALS AND REAGENTS 
 
Loperamide, terfenadine, testosterone, 6-β-OH-testosterone, phenacetin, 
dextromethorphan, dextrorphan, sodium selenite, zinc sulfate, all-trans retinoic 
acid, sodium hydroxide, Kreb’s Bicarbonate Ringer and gentamicin were 
purchased from Sigma Aldrich (St. Louis, MO, USA).  Metabolites of loperamide 
(monodemethyl- and didemethyl-loperamide) were generously provided by 
Janssen (Beerse, Belgium).  Metabolites of terfenadine (azacyclonol and 
fexofenadine) were generously provided by Dr. Mary Paine.   GW918 was 
provided by GlaxoSmithKline.  Methanol, formic acid, ethyl acetate vitamin E, 
and scintillation fluid (Scintisafe gel) were purchased from Fisher Scientific 
(Pittsburgh, PA, USA).  Ketamine was purchased from Veterinary Medical Supply 
(Zebulon, NC, USA), and xylazine from Webster Veterinary (Sterling, MA, USA).  
Eagle’s minimum essential medium with Earle’s salts and L-glutamate (MEM), 
Dulbecco’s Modified Eagle’s Medium with L-glutamine but without sodium 
pyruvate (DMEM), nonessential amino acids (NEAA, 100X), 0.05% trypsin-0.53 
mM EDTA solution, N-Hydroxyethylpiperazine-N’-2-ethanesulfonate (HEPES, 1 
M) and penicillin-streptomycin-amphotericin B solution (100X) were obtained 
from Gibco Laboratories (Grand Island, NY, USA).  Hank’s balanced salt solution 
(HBSS) was obtained from Mediatech, Inc. (Herndon, VA, USA).  1α, 25-
dihydroxyvitamin D3 was obtained from Biomol (Plymouth Meeting, PA, USA).  
Azamulin and mouse laminin were purchased from BD Biosciences (San Jose, 
CA, USA).  [3H]Digoxin and [3H]mannitol were purchased from Perkin Elmer 
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(Waltham, MA, USA) and Moravek (Brea, CA, USA), respectively.  All other 
reagents were of analytical grade or higher and deionized water was used in all 
experimental procedures.  [S]-mephenytoin, diclofenac, and their authentic 
metabolite standards were purchased from BD Gentest (Woburn, MA, USA). 
 
B. ANIMALS 
 
Mice (CF-1 wild type and P-gp mutant) were purchased from Charles River 
Laboratories (Wilmington, MA, USA) and housed according to AAALAC 
requirements and protocols (numbers 04-288 and 06-303) accepted by the 
University of North Carolina Institutional Animal Care and Use Committee.  The 
animal housing facility is under the supervision of the University’s Campus 
Veterinarian, and is in compliance with public laws 89-544 and 91-579.  A full-
time technician in the Department of Laboratory Animal Medicine is responsible 
for animal husbandry in this facility.  All personnel handling animals were first 
certified by the university Institutional Animal Care and Use Committee.   
 
C. MATERIALS 
 
Corning plates (12-well) with Transwell™ inserts were purchased from Fisher 
Scientific (Pittsburgh, PA, USA); 6-well-plates and inserts were purchased from 
BD Biosciences (San Jose, CA, USA).  The side-by-side diffusion chamber 
system (Physiologic Instruments, San Diego, CA, USA) used for the animal 
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studies was generously loaned to our lab by GlaxoSmithKline. Mouse liver and 
intestinal microsomes were purchased from Xenotech.  Human intestinal 
microsomes were generously provided by Dr. Mary Paine (School of Pharmacy, 
University of North Carolina, Chapel Hill, NC, USA). 
 
D. CACO-2 CELL CULTURE 
   
The Caco-2 cell line, clone P27.7, was obtained from Mary Paine, Ph.D. and 
Paul Watkins, MD (Schools of Pharmacy and Medicine, The University of North 
Carolina at Chapel Hill, Chapel Hill, NC, USA).  Caco-2 cell monolayers were 
cultured according to the methods of Lee and Thakker (Lee and Thakker, 1999).  
Except where noted, cell culture medium consisted of 500 ml Minimum Essential 
Medium (MEM), 50 ml Fetal Bovine Serum (FBS), 5 ml 100X Non-Essential 
Amino Acids (NEAA), and 5 ml 100X Antibiotic/Antimycotic (final concentrations: 
100 U/ml penicillin, 100 µg/ml streptomycin, and 0.25 µg/ml amphotericin B).  
Cells were grown in 75 cm2 tissue culture (T75) flasks at 37oC, in an atmosphere 
of 5% CO2 and 90% relative humidity, and subcultured at a 1:10 ratio, using 
0.05% trypsin/0.02% EDTA solution, upon reaching 90% confluency.   
 
 
 
E. TRANSWELL® SYSTEM 
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For transport experiments, the polycarbonate membranes of Transwell® 
inserts (12 mm, 0.4 µm pore size) in 12-well plates were seeded with 60,000 
cells per well (1 cm2) during subculture from T75 flasks.  Media was changed the 
day after seeding, and every other day thereafter.  Monolayer integrity was 
verified by measurement of TEER using an Epithelial Tissue Voltammeter 
(EVOM) and an Endohm-12 Electrode (World Precision Instruments, Saratoga, 
FL, USA). Monolayers with TEER ≥ 250 Ω·cm2 were used for experiments 
(passages 35-50). 
 
For metabolic experiments, 6-well plates containing Biocoat cell culture 
inserts (4.2 cm2, 1 µM pore size) were coated with murine laminin (5 µg/cm2) and 
then were seeded with Caco-2 cell clone P27.7 (passages 29-42) (Schmiedlin-Ren 
et al., 1997) at a density of 5 X 105 cells/cm2.  Cultures were grown using growth 
medium (DMEM containing 20% heat-inactivated FBS, 0.1 mM NEAA, 50 µg/ml 
gentamicin, and 45 nM vitamin E) until confluence, as assessed by transepithelial 
electrical resistance values 250 · cm2.  After that, the cells were treated for 14 
days with differentiation medium (DMEM containing 5% heat-inactivated FBS, 
0.1 mM NEAA, 50 µg/ml gentamicin, 45 nM vitamin E, 0.1 µM sodium selenite, 
and 3 µM zinc sulfate) as described by Schmeidlen-Ren et al. (Schmiedlin-Ren et 
al., 1997) and supplemented with 0.5 µM 1 ,25-(OH)2-D3 and 0.2 µM all-trans-
retinoic acid (Mouly et al., 2004) to induce CYP3A expression.  
F. TRANSPORT STUDIES 
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Transport experiments were carried out using Caco-2 cell monolayers, 21-28 
days post-seeding, as previously described (Lee and Thakker, 1999).  Transport 
medium was comprised of Hank’s Balanced Salt Solution (HBSS) containing 10 
mM HEPES buffer and 25 mM glucose.  Cell culture medium in Transwell plates 
was replaced with transport medium and the plates were incubated at 37oC for 
one hour before the experimental procedure.  Membrane integrity was then 
assessed by TEER or by use of a paracellular marker (lucifer yellow or mannitol).  
After warming dosing solutions, transport medium was replaced with dosing 
solution in the donor compartment, and with fresh warmed transport medium in 
the acceptor compartment.  Plates were maintained at 37oC throughout the 
experiment.  Samples were collected from the receiver compartment at 
appropriate timepoints.  At the final timepoint, the inserts were removed rapidly 
from the wells and inverted to end the incubation.  
 
G. UPTAKE STUDIES 
   
After a 30 minute preincubation, 0.5 ml of transport buffer containing 25 µM 
terfenadine was added to the donor compartment and incubated for 1 minute, 
after which cells were rinsed three times with ice-cold buffer.  Then cell 
monolayers were lysed in 1% Triton X-100, extracted into ethyl acetate (2 X 1 
ml), evaporated, and reconstituted in mobile phase for analysis.   
 
H. EFFLUX STUDIES 
 51 
 
In order to preload the intracellular space with terfenadine, 25 µM terfenadine 
was added to both apical and basolateral compartments and incubated for 1 
hour.  The cell monolayers were washed 3 times with ice-cold buffer.  Then fresh 
warmed buffer was added and samples were collected after one minute of efflux, 
which is within the linear range of efflux for terfenadine.  Cell monolayers were 
also extracted and analyzed for terfenadine content as described above. 
  
I. METABOLIC STUDIES 
 
To induce CYP3A expression, Caco-2 cell monolayers were grown on 
laminin-coated inserts in cell culture dishes, and treated with 0.5 µM 1 ,25-(OH)2-
D3 for 2 weeks postconfluence, as verified by TEER ≥ 250 Ω·cm2 (Schmiedlin-Ren 
et al., 1997; Mouly et al., 2004).  Transport studies were then conducted as 
described above.  At the last timepoint, samples were collected from the donor 
and receiver compartments.  Cell monolayers were washed and harvested by 
scraping into 500 µl of homogenization buffer (100 mM potassium phosphate, 
0.25 M sucrose, and 1 mM EDTA, pH 7.4).  CYP3A-specific metabolites were 
identified for each substrate, and metabolite formation over time was 
characterized by quantification of parent remaining and metabolite formed in all 
three compartments (donor, cellular and receiver). Terfenadine and its 
metabolites were extracted from the lysates using a validated extraction 
procedure.  Briefly, samples were disrupted with a sonic dismembrator for 15 
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seconds and then vortexed with 1 ml ethyl acetate, then centrifuged and the 
supernatant removed.  The samples were then alkalinized with 50 µl 1 N sodium 
hydroxide and extracted with an additional 1 ml ethyl acetate.  The supernatants 
were combined, evaporated, and reconstituted in mobile phase. 
 
J. DIFFUSION CHAMBER STUDIES 
   
Male CF-1 mice were anesthetized with an IP injection of ketamine (140 
mg/kg) and xylazine (15 mg/kg).  At the time of sacrifice, the intestines were 
removed and immediately flushed with 10 ml ice-cold Krebs Bicarbonate Ringer 
(KBR).  Three portions of jejunum (~1 inch long) were retained for the analysis.  
Each section was cut longitudinally and then mounted between the two halves of 
a diffusion chamber insert and held in place by eight small pins (Figure 2.1).  The 
inserts were placed in ice-cold KBR until mounted between the chambers.  The 
entire procedure was carried out as quickly as possible, on ice. 
 
Inserts were mounted between two side-by-side diffusion chambers.  KBR (3 
ml) was added to each chamber and bubbled with oxygen/carbon dioxide gas to 
maintain viability (Johnson et al., 2002).  After an equilibration period of 30 
minutes, the TEER was measured, the buffer in the receiver side was replaced 
with fresh warmed KBR, and the buffer in the donor side was replaced with 
warmed dosing solution.  Samples were removed from the chambers at the 
appropriate timepoints and replaced with fresh KBR.  At the end of the 
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experiment, the tissues were removed and homogenized for 30 seconds with a 
sonic dismembrator in 200 µL of KBR, then extracted with ethyl acetate as 
described for cell monolayers above. 
 
K. MICROSOME ASSAYS 
 
Mouse and human intestinal microsomes, total protein concentration 10 
mg/ml and 7.6 mg/ml, respectively, were used to determine the intrinsic kinetic 
parameters for each of these species.  Reactions were carried out in 200 µl 200 
mM phosphate buffer containing 3 mM MgCl2 and 0.1 mg microsomes.  
Reactions were initiated with 2 mM NADPH and were terminated after 30 
minutes by addition of ice-cold methanol.  Inhibitor concentration was 3 µM for 
both ketoconazole and quinidine and was 5 µM for azamulin.  A cassette dosing 
method was used to determine the activities of CYP enzymes in mouse and 
human intestinal microsomes, as previously described (Yanni et al., 2004). 
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L. ANALYSIS OF TERFENADINE  AND LOPERAMIDE AND THEIR METABOLITES 
 
Terfenadine and its two metabolites, fexofenadine and azacyclonol, and 
loperamide and its two metabolites, monodemethyl-loperamide and didemethyl-
loperamide, were quantified using LC-MS/MS (LC10-ADVP quaternary pumps 
(Shimadzu, Kyoto, Japan), CTC-PAL autosampler (LEAP Technologies, 
Carrboro, NC, Sciex API-4000 triple-quadropole mass spectrometer (Applied 
Biosystems, Foster City, CA).   
 
Mobile phases of 0.1% formic acid in water and 0.1% formic acid in methanol 
were used with a 5-95% methanol linear gradient.  The column used was a 
Phenomenex Synergy Polar RP, 30 X 2 mm, with 5 µm particle size phenyl-ether 
linked stationary phase.  A flow rate of 0.8 mL/min and injection volume of 15 µL 
were utilized.  Samples were ionized using APCI and ions were monitored at the 
following transitions: 472/436 for terfenadine, 503/466 for fexofenadine, 268/143 
for azacyclonol, 477/266 for loperamide, 463/252 for monodemethyl loperamide, 
and 449/238 for didemethyl loperamide.  Standards were available for each of 
the metabolites, allowing accurate quantification.   Standard curves were 
analyzed at the beginning and end of the run for sample quantification.  Cetirizine 
was used as an internal standard.  Retention times and peak shapes were 
monitored throughout the run. 
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M. ANALYSIS OF TESTOSTERONE AND 6-β-HYDROXYTESTOSTERONE 
 
Testosterone and its metabolite were quantified using HPLC (HP1100, Agilent 
Technologies, Santa Clara, CA) with UV detection at 242 nm.  Water and 
methanol were used as mobile phases, with a linear gradient from 40 to 75% 
methanol.  The column used was an Agilent Zorbax Eclipse XDB-C8, 4.6 X 150 
mm, with 5 µm particle size packing.  A flow rate of 0.8 mL/min and an injection 
volume of 50 µL were employed.  A standard curve was analyzed for sample 
quantification.  Five injections of an intermediate standard were analyzed for 
system suitability and injection reproducibility (<2.0% RSD).  Retention time and 
peak shape were monitored throughout the run. 
 
N. ANALYSIS OF [3H]DIGOXIN AND [14C]MANNITOL 
 
Samples were combined with 10 ml scintillation fluid and analyzed using a 
Packard scintillation counter. 
 
O. PHARMACOKINETIC MODELING 
 
WinNonlin (Pharsight, Mountain View, CA) was used for all pharmacokinetic 
modeling.  A Guass-Newton minimization method and a weighting scheme of 1/y 
were used for all modeling exercises.  In addition to visual inspection, Akaike’s 
Information Criterion was used to determine the best model fit to the data.  Model 
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A consisted of three parent drug compartments, plus one pathway for metabolite 
formation (Figure 3.24).  The model was fit to the Caco-2 cell metabolic data for 
terfenadine (see Chapter 3).  Refer to Table 3.2 for rates used in the modeling.  
The metabolite formation profiles from six doses were fit simultaneously by using 
24 distinct differential equations.  For each dose, four equations with the 
following structure were used: 
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Where Vmax is the maximum rate of metabolite formation, Km is the 
concentration of substrate at which half of maximum velocity is achieved, and k 
constants represent the various first-order rate constants for movement of mass 
between compartments, e.g., kAB represents the rate of drug movement from 
compartment A to compartment B.  Simulations were then carried out to 
determine the effect of P-gp efflux (kBA) on metabolic rate (dD/dt).   
 
CYP3A expression is known to be highest in proximal intestine, while P-gp 
expression increases distally (Figure 4.2).  To simulate different expression 
levels of CYP3A, Vmax was systematically altered while the other parameters 
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were held constant.  To determine the effect of changes in P-gp expression, the 
function kBA*B was replaced with a saturable component, yielding: 
BK
BJ
mpgp +
max
  
Where Jmax represents the maximum rate of efflux and Kmpgp represents the 
concentration at which half of Jmax is attained.  Using these modified equations, 
the effect of changing Jmax was investigated, while Kmpgp and all other parameters 
were held constant.  A matrix of simulations consisting of various combinations of 
Vmax and Jmax values was generated in this manner. 
 
To evaluate the parameters that are used to describe the relationship 
between P-gp activity and metabolic rate, a set of simulations were carried out by 
altering Jmax and observing the effect on % metabolized and extraction ratio.  The 
extraction ratio (ER) was calculated in two different ways.  The first was based on 
the methods of Fisher et al. (Fisher et al., 1999): 
   
∑
∑
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M  M
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    ER          
    
where Mmetabolites is the cumulative mass of all metabolites from all compartments 
at time t and Mout is the parent compound appearing in the receiver compartment 
at time t.  The second equation was derived from Benet et al. (Benet et al., 2004); 
they modified the ER definition to include the amount of intracellular parent drug 
 58 
(Mparent) in the denominator of the above equation to produce the following 
equation:   
 
∑
∑
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= ) (at time M M  M
M
parentoutsmetabolite
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ER                  
Both methods of calculating ER were used to compare the effect of P-gp efflux 
on these parameters and also on percent of dose metabolized (metabolites 
formed/dose). 
 
 A second PK model was also designed (Model B, Figure 3.30) which 
incorporated an extra compartment for P-gp between the apical and cellular 
compartments.  Since data were not available for this compartment, the rate 
constants kAB, kBC and kCB were assumed to be equal.  Simulations were then 
carried out as described above to determine the effect of changes in P-gp efflux 
(kBA) on the CYP3A-mediated metabolism of dual substrates. 
 
P. DATA ANALYSIS 
 
All samples were prepared in triplicate.  The permeability (Papp) of substrates 
across cell monolayers was calculated as follows: 
CA
dtdQPapp
*
/
=           Equation 1 
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where dQ/dt represents the mass transported per time, A is the area of the 
membrane, and C is the initial concentration of drug in the donor compartment.  
This equation assumes sink conditions (Karlsson and Artursson, 1991). 
For the metabolic studies, a Michaelis-Menten model (Equation 2) was fit to the 
data: 
CK
CVV
m +
=
*max
             Equation 2  
where V represents the rate of metabolism, Vmax is the maximum rate observed, 
Km is the concentration at which half of the maximum velocity is achieved, and C 
is the dosing concentration.  All metabolic data were fit using WinNonlin software 
(Pharsight, Mountain View, CA). 
 
 The overall difference between strains or treatments was determined 
using two-way analysis of variance.  To estimate the difference in kinetic 
parameters (Vmax and Km), the data for the two strains or treatments were fit 
simultaneously using nonlinear regression analysis.  The null hypotheses of H0: 
Km1 = Km2  and H0: Vmax1 = Vmax 2 were then tested. 
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DOSESAMPLE
 
Figure 2.1. Side-by-side diffusion chamber schematic: mouse jejunum is 
flushed, cut longitudinally, and placed in a holder between two chambers, 
which are oxygenated to maintain viability.  
CHAPTER 3: RESULTS
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A.  MODEL VALIDATION 
 
A.1. Caco-2 Cell Model 
 
A.1.a. Functional Activity of P-gp 
 
In order to validate the Caco-2 cell system and demonstrate P-gp efflux 
activity, the permeability of the model P-gp substrate [3H]digoxin (10 µM) was 
characterized over 90 minutes.  As shown in Figure 3.1, the permeability of 
[3H]digoxin in the basolateral-to-apical (B-to-A) direction was approximately 8-fold 
higher than that in the A-to-B direction.  In the presence of P-gp inhibitor GW918 
(1 µM), this polarity was abolished: B-to-A and A-to-B permeabilities were equal.  
These results established that the Caco-2 cells used in this study have functional 
P-gp and that it can be completely inhibited by 1 µM GW918. 
 
A.1.b. Functional Activity of CYP3A 
 
A CYP3A-expressing Caco-2 cell system was implemented by treatment of 
Caco-2 cells with 1α,25-dihydroxyvitamin D3 for 14 days (Schmeidlen-Ren et al., 
1997).  In order to verify the activity of CYP3A in the Caco-2 cell system, the 
CYP3A-specific activity (6-β-hydroxylase activity) of the cells toward testosterone 
(250 µM) was measured over 120 minutes.  CYP3A activity was shown to be 
reproducibly induced in the cells (Figure 3.2).  Although P-gp is also somewhat 
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induced by this treatment, the effect is not likely to be significant since chemical 
modulation of P-gp is used in these studies rather than comparison of 
metabolism in induced and uninduced cells. 
 
A.2. Mouse Intestinal Tissue Model 
 
To validate the side-by-side diffusion model system, the permeability of the P-
gp probe substrate [3H]digoxin was measured over 90 minutes to demonstrate P-
gp function.  As seen in Figure 3.3, B-to-A permeability was approximately 3-fold 
higher than A-to-B permeability in the wild-type mouse, while in the P-gp deficient 
mouse, the B-to-A and A-to-B permeabilities were similar.  These results showed 
that the side-by-side diffusion model, in which intestinal tissue from P-gp 
competent and P-gp deficient mouse is mounted in an Ussing type chamber, can 
be used to investigate the effect of P-gp on intestinal transport of compounds. 
The permeability of the paracellular marker [14C]mannitol was also measured to 
determine the paracellular leakiness of the system.  As shown in Figure 3.4, 
[14C]mannitol permeability was about 35 ± 12 nm/sec, which is about 10-fold 
higher than that normally observed in the Caco-2 cell system but is similar to 
previously reported values for rodent intestine (Stephens et al., 2002).  The higher 
paracellular permeability of the diffusion chamber model compared to the Caco-2 
cell model may account for the lower polarity of digoxin transport in this system. 
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Since genetic knockout of a protein sometimes results in compensatory 
upregulation of a different pathway, studies were performed to compare CYP3A 
expression and activity in the P-gp-competent and –deficient mouse strains.  No 
difference in intestinal metabolic activity toward the CYP3A probe substrate 
testosterone was observed over 90 minutes (Figure 3.5).  Since testosterone is 
not a substrate for P-gp, this result provides evidence that CYP3A expression is 
not altered in the P-gp knock-out mouse model.  In addition, no difference was 
observed in intestinal CYP3A expression by Western blot (data not shown).   
 
B.  LOPERAMIDE – INTESTINAL TRANSPORT AND METABOLISM 
 
B.1. Transport and Metabolism in the Caco-2 Cell Model 
 
The dual P-gp/CYP3A substrate loperamide was chosen to study the 
interaction between P-gp and CYP3A in the intestine.  Loperamide is a lipophilic 
compound with excellent permeability across intestinal epithelium; however, its 
absorptive transport is significantly affected by P-gp (see Figure 3.6).  Using the 
approach established by Troutman and Thakker (Troutman and Thakker, 2003), it 
was estimated that P-gp attenuated loperamide’s absorptive permeability by 
approximately 60%.  This provides an adequate dynamic range for P-gp-
mediated attenuation of absorptive transport for the purpose of studying its effect 
on CYP3A-mediated metabolism.  The transport of loperamide (0.25 µM) across 
Caco-2 cell monolayers was characterized over 60 minutes in the A-to-B and B-
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to-A directions; the P-gp inhibitor GW918 was used to assess the effect of P-gp 
on loperamide transport in both directions.  The B-to-A permeability of 
loperamide was about 6-fold higher than the A-to-B permeability; however, in the 
presence of GW918 (1 µM), this polarity was abolished (Figure 3.6), indicating 
that P-gp is likely to be the transporter responsible for the polarity. 
 
For the metabolism studies, two CYP3A-specific metabolites of loperamide 
(monodemethyl- and didemethyl-loperamide, Figure 3.7) were quantified by LC-
MS/MS.  The metabolism of loperamide was studied during its absorptive 
transport across Caco-2 cells that were induced to express functional CYP3A by 
treatment with 1α, 25-dihydroxyvitamin D3.  This treatment has been shown to 
modestly elevate P-gp expression levels, but no effect was seen on the 
permeability of model P-gp substrates (Korjamo et al., 2005).  In order to determine 
the linear range of time for metabolite formation, an initial study was conducted in 
which metabolites in the receiver compartment were quantified at three time 
points (30, 60, and 90 minutes) after a 20 µM dose of loperamide.  Loperamide 
metabolism was found to be linear up to 90 minutes (Figure 3.8).   
 
Next, studies were conducted over a range of loperamide dosing 
concentrations from 1 to 75 µM (bounded by the detection limit of metabolites 
and solubility of loperamide) in the presence and absence of the P-gp inhibitor 
GW918.  Metabolites of loperamide appearing in the apical, basolateral and 
cellular compartments over 90 minutes were quantified by LC-MS/MS.  A higher 
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rate of metabolism was observed in the presence of 1 µM GW918 at every 
dosing concentration up to and including 40 µM (Figure 3.9).  Simultaneously 
fitting the profiles using nonlinear regression with a dummy variable determining 
the differences between Vmax and Km values for the two treatments showed a 
statistically significant two-fold increase in the apparent Km value due to P-gp 
efflux.  Presumably, P-gp efflux affected the apparent Km for metabolism (Table 
3.1) by effectively decreasing steady-state intracellular concentrations of the 
parent drug.  No difference was seen in the Vmax values using this statistical 
method, although the Vmax may not be estimated accurately due to the large 
variability observed at the 75 µM dose (presumably, due to the solubility limit).  
The metabolic profiles were also analyzed using two-way analysis of variance 
(ANOVA).  This statistical method tests the null hypothesis that the overall rate 
versus concentration profiles are not different.  A statistical difference between 
the profiles was found using this method. 
 
B.2. Transport and Metabolism in the Mouse Intestine – Diffusion 
Chamber Model 
 
The next set of experiments involved the use of side-by-side diffusion 
chambers to compare the metabolic activity of fresh intestinal tissues from P-gp-
competent and P-gp-deficient mice.  A dosing range of 0.5 to 150 µM of 
loperamide was used.  Three mice were utilized for each dosing concentration 
and three sections of jejunum were used from each mouse.  At dosing 
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concentrations below 100 µM, intestinal tissues from P-gp-deficient mice 
metabolized loperamide at a higher rate than the tissues from P-gp-competent 
mice, causing a rightward shift in the metabolic rate versus concentration profile 
for the P-gp competent mice, relative to the profile for P-gp-deficient mice (Figure 
3.10). When a Michaelis-Menten nonlinear function (Equation 2) was fit to the 
data, it was revealed that CYP3A in the P-gp-competent mouse intestinal tissue 
metabolized loperamide with a significantly (5-fold) higher apparent Km than that 
for P-gp-deficient mouse intestinal tissue, although CYP3A from both tissues 
exhibited similar Vmax values (Table 3.1), indicating that there is no intrinsic 
difference in CYP3A-mediated metabolism of loperamide between the two 
strains.  The profiles for the two strains of mice were also shown to be 
significantly different using two-way ANOVA. 
 
B.3. Metabolism by Intestinal Microsomes 
 
In order to derive the intrinsic metabolic parameters for loperamide, the 
metabolism of loperamide was compared in mouse and human intestinal 
microsomes (Figure 3.11).  The CYP3A-mediated metabolism was similar in the 
two species.  The Km values were nearly identical, while the Vmax for mouse 
intestinal microsomes was about 4-fold higher than that for human (Table 3.1). 
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C. TERFENADINE – INTESTINAL TRANSPORT AND METABOLISM 
 
C.1. Transport and Metabolism in the Caco-2 Cell Model 
 
A second P-gp/CYP3A dual substrate, terfenadine, was selected for further 
study of the P-gp/CYP3A interaction in intestine.  Terfenadine’s absorptive 
transport is attenuated to a lesser extent (40%, AQ value 0.4) by P-gp than that 
of loperamide (60%, AQ value 0.6).  Thus, studies were conducted to determine 
whether two P-gp substrates whose absorptive transport is attenuated by P-gp to 
a different extent are affected differently with respect to their CYP3A-mediated 
metabolism.  Terfenadine was chosen as a second P-gp/CYP3A dual substrate 
because the physico-chemical and permeability properties of terfenadine are 
similar to that of loperamide - both are lipophilic, poorly soluble, and have high 
permeability across intestinal epithelium – and yet P-gp-mediated attenuation of 
its absorptive transport was significantly lower than that of loperamide.  First, the 
transport of terfenadine across Caco-2 cell monolayers was characterized in the 
A-to-B and B-to-A directions, and also in the presence and absence of the P-gp 
inhibitor GW918.  As shown in Figure 3.12, the apparent permeability in the B-to-
A direction was approximately 8-fold higher than in the A-to-B direction under 
control conditions.  The absorptive permeability was significantly enhanced (~3 
fold) in the presence of P-gp inhibitor GW918, suggesting that absorptive 
transport of terfenadine is reduced by P-gp.  However, the B-to-A permeability 
remained significantly greater than the A-to-B permeability even in the absence 
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of P-gp (and presumably BCRP) activity (GW918 at 1 µM concentration 
completely inhibits P-gp and BCRP).  This trend was observed at several dosing 
concentrations (Figure 3.13) and suggests that an additional AP efflux 
transporter may be involved in terfenadine’s transport across Caco-2 cell 
monolayers.  It appears that the factors affecting the permeability are more 
complex for terfenadine than for loperamide.   
 
Next, the metabolism of terfenadine was studied during its absorptive 
transport across Caco-2 cells that were induced to express functional CYP3A by 
treatment with 1α, 25-dihydroxyvitamin D3.  CYP3A-specific metabolites of 
terfenadine (fexofenadine and azacyclonol) (Figure 3.14) appearing in the apical, 
basolateral and cellular compartments were quantified by LC-MS/MS (Figure 
3.15).  Studies were conducted over a range of dosing concentrations (1 to 50 
µM, bounded by the detection limit of metabolites and cellular toxicity of 
terfenadine) in the presence and absence of the P-gp inhibitor GW918.  As 
shown in Figure 3.15, the difference between the rates of metabolite production 
in GW918 treated and untreated cells was not significant; this was concluded 
using either simultaneous curve fitting or two-way ANOVA.  This is in contrast 
with the results obtained for loperamide, whose CYP3A-mediated metabolism 
was reduced by P-gp (Figure 3.9).  
 
The metabolic pathways of terfenadine are represented in Figure 3.14.  
Interestingly fexofenadine, one of the metabolites of terfenadine, is a better 
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substrate of P-gp than its parent compound (AQ for fexofenadine is 0.97, 
compared to 0.43 for terfenadine).  As shown in Figure 3.16, fexofenadine 
exhibited over a 30-fold higher permeability in the B-to-A direction than in the A-
to-B direction.  In the presence of P-gp inhibitor GW918, the absorptive 
permeability of fexofenadine increased and the secretory permeability 
decreased, yielding nearly equal values.  Consistent with its status as a P-gp 
substrate, fexofenadine was primarily effluxed to the apical compartment when it 
was formed within the cells after an apical dose of terfenadine; however, in the 
presence of GW918, fexofenadine was primarily found in the basolateral 
compartment (Figure 3.17), implying the presence of a basolateral efflux 
mechanism that does not appear to compete effectively with P-gp but directs the 
efflux of fexofenadine predominantly to the basolateral compartment when P-gp 
is inhibited. The distribution of the other metabolite of terfenadine, azacyclonol, 
remained unchanged in the presence of GW918 (Figure 3.17).  The relative 
distribution of fexofenadine into the apical and basolateral compartments was 
also examined in the presence of MK571 (25 µM), an inhibitor of MRP (multidrug-
resistance associated protein) transporters.  The distribution remained 
unchanged with respect to the control, although the metabolic rate seemed to 
decrease slightly (Figure 3.18).  However, when combined with GW918, MK571 
reduced, but did not eliminate, the polarity of fexofenadine efflux toward the 
basolateral side; this suggested that fexofenadine efflux across the basolateral 
membrane is mediated, at least in part, by one or more MRP family 
transporter(s). 
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C.2. Transport and Metabolism in the Mouse Intestine - Diffusion 
Chamber Model 
 
In the diffusion chamber model, a dosing range of 0.2 to 50 µM was used for 
terfenadine.  For dosing concentrations up to 25 µM, intestinal tissues from P-gp-
deficient mice metabolized terfenadine at a higher rate than the tissues from P-
gp-competent mice, causing a rightward shift in the metabolic rate versus 
concentration profile, relative to the profile for P-gp-deficient mice (Figure 3.19). 
When a simple Michaelis-Menten model (Equation 2) was fitted to the data, it 
was revealed that CYP3A in the P-gp-competent mouse intestinal tissue 
metabolized terfenadine with about a four-fold higher apparent Km than that 
observed for P-gp-deficient mouse intestinal tissue, with CYP3A from both 
tissues exhibiting similar Vmax values (Table 3.1).  The overall profiles were also 
found to be statistically different using two-way ANOVA.  
 
C.3. Metabolism by Intestinal Microsomes 
 
The intrinsic kinetic parameters were determined for terfenadine metabolism 
by human intestinal microsomes (Figure 3.20) and mouse intestinal microsomes 
(Figure 3.21).  Although the apparent Km values for metabolism of terfenadine 
during absorptive transport across Caco-2 cell monolayers and across fresh 
mouse intestinal tissue from P-gp competent mice were similar, the Km for its 
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metabolism by human intestinal microsomes was 24-fold higher than that 
obtained with mouse (P-gp competent) intestinal microsomes; the results are 
summarized in Table 3.1.    These results suggested that different CYPs may 
metabolize terfenadine in the mouse vs. human intestine. Hence, CYP-selective 
inhibitors were used to determine the contribution of CYP3A (and possibly other 
CYP enzymes) to the intestinal metabolism of terfenadine.  Interestingly, 
terfenadine metabolism by mouse intestinal tissue was inhibited only partially by 
ketoconazole (3 µM), a compound that is expected to inhibit CYP3A completely 
at this concentration (Figure 3.22).   Since terfenadine is known to be 
metabolized by CYP2D6 in human liver (Jones et al., 1998), the contribution of this 
CYP in its metabolism by microsomes from mouse and human intestinal tissue 
was assessed by using CYP2D inhibitor, quinidine (3 µM).  The results in Figure 
3.22 show that CYP3A and CYP2D each contribute approximately 60% of the 
total oxidative metabolism of terfenadine.  Clearly, this implies that one of the 
inhibitors, likely ketoconazole, is inhibiting the second CYP to some extent.  
Hence, another CYP3A-specific inhibitor, azamulin, was used to determine the 
contribution of CYP3A to terfenadine metabolism.  Azamulin (5 µM) was only 
able to inhibit terfenadine metabolism by 41% in mouse intestinal microsomes; 
thus it appears that CYP3A and CYP2D contribute ~40% and 60% of the total 
oxidative metabolism of terfenadine in mouse intestine.  In order to help 
understand the significant contribution of CYP2D to the mouse intestinal 
metabolism of terfenadine, activities of five major CYP isoforms, CYP1A1, 
CYP2D6, CYP2C9, CYP2C19 and CYP3A4, in the human intestine were 
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compared to the orthologous activities in the mouse intestine using a cassette 
dosing method (Yanni et al., 2004).  As shown in Figure 3.23, most of the activities 
were similar in the mouse and human intestinal microsomes except for the 
activity of CYP2D (formation of dextrorphan from dextromethorphan), which was 
approximately 25-fold higher in mouse intestinal microsomes.  This result is 
consistent with the inhibition profile observed for terfenadine in mouse intestinal 
microsomes, which shows that CYP2D plays a greater role than CYP3A in the 
metabolism of terfenadine. 
 
 
D.  PHARMACOKINETIC MODELING OF P-GP/CYP3A INTERACTIONS DURING 
TRANSPORT OF DUAL SUBSTRATES 
 
 
The rate of apical uptake, as well as the basolateral efflux rate, was 
determined for terfenadine in Caco-2 cell monolayers.  The results are shown in 
Table 3.2.  In addition, the intrinsic Km for terfenadine metabolism was 
determined using human intestinal microsomes.  A simple Michaelis-Menten 
model was fit to the microsome data and the Vmax and Km were determined using 
WinNonlin.  However, for the PK modeling exercises, the Vmax for metabolism 
determined from Caco-2 cells was used in order to more accurately reflect the 
expression level of CYP3A in the Caco-2 cell system. 
 
The basic model that describes translocation of compounds, with dual 
substrate activity for efflux transporters and metabolic enzymes, across intestinal 
epithelium is shown in Figure 3.24.  Model A consists of three compartments, 
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and incorporates the following assumptions: the function describing metabolism 
is saturable; uptake into the cell across apical and basolateral membranes and 
efflux across the basolateral membrane is via passive diffusion; efflux across the 
apical membrane, mediated by P-gp, occurs at concentrations that are not likely 
to saturate P-gp; P-gp and CYP3A, although in different membrane 
compartments (apical membrane and endoplasmic reticulum, respectively), are 
assumed to be acting on the same cytosolic concentration of their dual 
substrates.  Model A adequately described terfenadine efflux-metabolism 
interactions during absorptive transport across Caco-2 cell monolayers (Figure 
3.25).  In order to predict the effect of P-gp efflux on metabolic rate, a series of 
profiles were simulated at different values of the P-gp efflux rate constant, kBA.  
As P-gp efflux rate increased, metabolite formation rate proportionally decreased 
(Figure 3.26).  
 
As shown in Figure 3.27, P-gp expression increases in the distal regions of 
intestine, while CYP3A expression decreases (Liu et al., 2006).  When the effect of 
varying expression levels of P-gp and CYP3A was investigated through 
simulations, metabolism was found to decrease with increasing P-gp expression 
or decreasing CYP3A expression (Figure 3.28).  Interestingly, at high P-gp 
expression (Jmax), changes in Vmax (related to expression of CYP3A) had less of 
an effect on the rate of metabolism, suggesting that high expression of P-gp 
could buffer the metabolic changes due to differential expression of metabolic 
enzymes. 
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Several different parameters have been used by different groups to quantify 
the effect of P-gp efflux on CYP3A metabolism.  Therefore, a simulation exercise 
was carried out to determine the sensitivity of these parameters to changes in P-
gp efflux without changes in metabolic parameters.  While the percent of dose 
metabolized decreased slightly with an increase in P-gp efflux activity, the ER 
increased significantly, regardless of the method of calculation used (Figure 
3.29).  
 
Although Model A was able to adequately describe the Caco-2 cell data for 
terfenadine, it is recognized that this model is oversimplified and therefore may 
not be entirely representative of the in vivo situation.  Particularly, the assumption 
that P-gp and CYP3A act on the same (cytosolic) concentration of substrate may 
not be accurate.  Therefore, a secondary model (Model B, Figure 3.30) was 
developed which does not rely on this assumption.  The model incorporates a 
fourth “P-gp” compartment between the apical and cellular chambers.  However, 
the addition of the fourth compartment precludes fitting the model to experimental 
data, since no data is available for the additional compartment.  Therefore, an 
additional assumption was made: that the passive diffusion constants in and out 
of the “P-gp” compartment are equal; that is, kAB = kBC = kCB. 
 
      Using Model B, the effects of changes in P-gp efflux activity (kBA) on 
metabolism of dual substrates were simulated.  As shown in Figure 3.31, the 
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amount of metabolites produced over time decreased with increased P-gp 
activity.  This is similar to the result produced by Model A, except that with Model 
B increased P-gp activity seemed to lead to an increased lag time for CYP3A-
mediated metabolism.  These simulations are consistent with those performed 
using the previous model and are in agreement with the experimental results.
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Table 3.1. Kinetic parameters of metabolism of terfenadine and loperamide for 
CYP3A-expressing Caco-2 cells with or without P-gp inhibitor GW918; for P-gp 
competent and P-gp deficient mouse intestine; and for mouse and human 
intestinal microsomes. 
Parameter Caco-2 
No GW918 
Caco-2 
GW918 
WT 
Mouse 
KO 
Mouse 
MIM HIM 
LOP Vmax 0.80 ± 0.11 0.76 ± 0.06 31 ± 2.1 30 ± 3.2 102 ± 4.0 25 ± 2.0 
LOP Km 18 ± 4.0 8.6 ± 1.6 22 ± 4.8 4.5 ± 2.4 0.93 ± 0.18 0.94 ± 0.26 
TF Vmax 0.5 ± 0.1 0.6 ± 0.0 21 ± 5.6 18 ± 2.9 36 ± 2.4 67 ± 9.7 
TF Km 9.6 ± 2.6 12 ± 2.2 14 ± 5.5 4.0 ± 2.4 0.9 ± 0.2 24 ± 7.1 
Vmax = pmol/min/cm2 for Caco-2 and mouse, pmol/min/mg for microsomes; Km = µM; WT = LOP 
= loperamide; TF = terfenadine; WT = P-gp competent mouse; KO = P-gp deficient mouse; MIM 
= mouse intestinal microsomes; HIM = human intestinal microsomes. Mean ± SD 
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Table 3.2. Parameters used in fitting 
the PK model to terfenadine data.   
Parameter Value 
Apical uptake 0.18 ml/min 
Basolateral efflux 0.0035 ml/min 
Vmax 2.1 pmoles/min 
Km 23.9 pmoles/ml 
Apical efflux 119 ml/min 
All parameters were experimentally derived 
besides the apical efflux rate, which was fitted 
using the model (CV = 1.2%).  Apical uptake 
and basolateral efflux determined over 1 
minute.  Vmax derived from Caco-2 metabolic 
data; Km derived from human intestinal 
microsomes. 
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Figure 3.1. Digoxin permeability over 90 minutes in 
Caco-2 after a 10 µM dose.  
N=3 ± SD. Black bars = control, gray bars = 
GW918 (1 µM) treatment.  Treated and untreated 
wells were found to be significantly different using 
student’s t-test (p<0.05).  Likewise, A to B 
permeability was statistically different than B to A 
permeability in the absence of inhibitor. 
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Figure 3.2.  Formation of 6-β-OH-testosterone over 120 
minutes from a 250 µM dose of testosterone in Caco-2 cells 
treated with 0.5 µM of 1α, 25-dihydroxyvitamin D3 for 14 
days versus untreated cells.  Metabolites were not 
detectable in the untreated cells. N=5; errors bars denote 
standard deviation. 
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Figure 3.3. Digoxin permeability over 90 minutes 
across mouse intestine in Ussing chamber after a 
10 µM dose.  N=3; error bars = SD; WT = P-gp 
competent mouse; KO = P-gp deficient mouse.  A-
to-B permeability is significantly different 
(student’s t-test, p<0.05) than B-to-A permeability 
in the WT only. 
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Figure 3.4. Mannitol absorptive transport across 
mouse intestinal tissue after a 5 µM dose.  
Permeability = 35 ± 12 nm/sec. n=3; error bars = SD; 
DPM = disintegrations per minute. 
 85 
Dose (mM)
0.0 0.2 0.4 0.6 0.8 1.0 1.2
pm
o
l/m
in
/c
m
2
0.0
0.2
0.4
0.6
0.8
1.0
WT
KO
 
Figure 3.5. CYP3A activity (testosterone 6-β-
hydroxylation) in P-gp-competent (WT) and P-
gp-deficient (KO) mouse intestine over 90 
minutes.   
Error bars denote standard deviation.  No 
significant difference was seen at any 
concentration level. 
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Figure 3.6. Absorptive and secretory 
transport of loperamide (0.25 µM dose) 
across Caco-2 cell monolayers in the 
presence versus absence of P-gp inhibitor 
GW918 (1 µM) over 60 minutes.  
n=3, error bars denote standard deviation.  
A significant difference was seen between 
treated and untreated wells for both 
directions.  In the untreated wells, a 
signficiant difference was observed in the 
A-to-B versus B-to-A directions (student’s 
t-test, p<0.05). 
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Figure 3.7. Structure of loperamide and its CYP3A metabolites, 
monodemethyl- and didemethyl-loperamide. 
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Figure 3.8. Linearity of loperamide 
metabolite formation during absorptive 
transport across Caco-2 cell 
monolayers.   
Dose = 20 µM, n=3, error bars = 
standard deviation.  A statistically 
significant difference was observed 
between treated and untreated wells at  
the 60 and 90 minute timepoints 
(p<0.05, student’s t-test). 
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Figure 3.9. Loperamide metabolism during 
absorptive transport across Caco-2 cell 
monolayers.   
n=3; error bars denote standard deviation.  
Profiles are statistically different (two-way 
ANOVA).  Lines represent the fit of the model 
to the data. 
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Figure 3.10. Loperamide metabolism by 
fresh intestinal tissue from P-gp 
competent (WT) and P-gp deficient (KO) 
mice.   
n=3; error bars denote standard 
deviation.  Profiles are statistically 
different (two-way ANOVA).  Lines 
represent the fit of the model to the data. 
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Figure 3.11. Metabolism of loperamide in mouse and human intestinal 
microsomes over 10 minutes.   
n=3; error bars denote standard deviation. Lines represent the fit of the 
Michaelis-Menten model to the data. 
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Figure 3.12. Permeability of terfenadine (20 µM 
dose) across Caco-2 cell monolayers in the 
absence (left) or presence (right) of 1 µM P-gp 
inhibitor GW918.   
Black bars represent apical to basolateral 
permeability; gray bars, basolateral to apical 
permeability.  Mean of 2 experiments with 3 
wells/experiment.  Error bars represent standard 
deviation.  A statistically significant difference was 
observed between A-to-B and B-to-A permeability 
for both the treated and untreated conditions.   A 
significant difference between treated and 
untreated wells was observed in the A-to-B 
direction only (p<0.05, student’s t-test). 
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Figure  3.13. A-to-B and B-to-A permeability 
of terfenadine in Caco-2 cell monolayers as a 
function of concentration. Upper panel: apical 
to basolateral transport; lower panel: 
basolateral to apical transport. 
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Figure 3.14. Structure of terfenadine and its 
metabolites formed by CYP3A. 
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Figure 3.15. Caco-2 metabolism of terfenadine 
over 120 minutes at several dose levels in the 
presence (open circle) or absence (closed 
circle) of 1 µM of the P-gp inhibitor GW918.  
Cells showed toxicity at doses above 50 µM. n 
= 3; error bars = standard deviation.  Lines 
represent the fit of the model to the data.  No 
significant difference was found between the 
two profiles (two-way ANOVA).   
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Figure 3.16. Permeability of 
fexofenadine (5 µM) across Caco-2 cell 
monolayers in the absence (left) or 
presence (right) of 1 µM P-gp inhibitor 
GW918.   
Black bars represent apical to 
basolateral permeability; gray bars, 
basolateral to apical permeability. 
Mean of 3; error bars = standard 
deviation.  Data from wells treated with 
GW918 is significantly different than 
control wells; A-to-B permeability was 
significantly different than B-to-A 
permeability in the untreated wells only 
(student’s t-test, p<0.05).   
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Figure 3.17.  Distribution of metabolites of 
terfenadine after a 20 µM apical dose in Caco-2 cells.   
N=3; error bars = SD.  Aza = azacyclonol; Fex = 
Fexofenadine; 918 = GW918; black bars = apical 
chamber; gray bars = basolateral chamber.  Amounts 
in apical and basolateral chamber are statistically 
different for all conditions (p<0.05, student’s t-test). 
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Figure 3.18. Fexofenadine distribution in 
induced Caco-2 cells in the absence or 
presence of inhibitors of P-gp (GW918) 
and MRP (MK571).   
N=3; error bars = SD; black bars = apical 
compartment; gray bars = basolateral 
compartment.  Amounts in apical and 
basolateral chamber are statistically 
different for all conditions (p<0.05, 
student’s t-test). 
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Figure 3.19. Terfenadine metabolism in P-gp-competent 
(WT, solid circles) and P-gp-deficient (KO, open circles) 
mouse intestine.   
Solid and dotted lines represent the fit of the model to the 
data for P-gp-competent and P-gp-deficient mice, 
respectively.  N = 3; error bars denote standard deviation.  
Profiles were found to be statistically different (two-way 
ANOVA). 
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Figure 3.20. Terfenadine metabolism by 
human intestinal microsomes. 
N=3; error bars = SD. Line represents the fit 
of a simple Michaelis-Menten model to the 
data. 
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Figure 3.21. Terfenadine metabolism by mouse 
intestinal microsomes.   
N=3; error bars = SD.  Lines represent the fit of 
a simple Michaelis-Menten model to the data. 
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Figure 3.22. Terfenadine metabolite formation and 
inhibition in mouse intestinal microsomes.   
N=3; error bars = SD.  AZM = azamulin, 5 µM; QDN = 
quinidine, 3 µM; KETO = ketoconazole, 3 µM. Incubation 
time = 10 minutes.  All treatments showed a statistically 
significant decrease relative to control (p<0.05, student’s 
t-test). 
 103 
CYP1A CYP2D CYP2C9 CYP2C19 CYP3A
pm
o
l/m
in
/m
g
0
20
40
60
80
100
120
140
160
MIM 
HIM 
 
Figure 3.23.  Metabolic activity of mouse intestinal microsomes (MIM) and 
human intestinal microsomes (HIM) toward P450 probe substrates:  
CYP1A2, phenacetin; CYP2D6, dextromethorphan; CYP2C9, diclofenac; 
CYP2C19, S-mephenytoin; CYP3A4, testosterone.  N=3; error bars = SD. 
MIM = black bars; HIM = gray bars. (Only human isoforms listed.)  
Statistical differences were shown between mouse and human intestinal 
microsomal activity for all isoforms listed besides CYP1A and CYP2C19 
(p<0.05, student’s t-test). 
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Figure 3.24. PK Model A. Three-compartment model 
describes the interplay between P-gp-efflux and 
CYP3A-mediated metabolism of dual substrates in the 
intestine.  k values represent first-order rate constants 
for compound movement between compartments; Vmax 
is the maximum rate of velocity achieved; Km is the 
concentration at which half of maximum metabolic 
velocity is achieved. 
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Figure 3.25. Line represents the fit of PK Model A to 
terfenadine Caco-2 data.  N=3; error bars = SD.   
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Figure 3.26. Simulation of the effect of increased P-gp efflux 
on amount of metabolites formed over time using Model A.  
kba represents the first-order rate constant for P-gp efflux. 
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Figure 3.27. Expression of P-gp and CYP3A (by Western blot) in rat 
intestine.  PCN = pregnenolone 16α–carbonitrile (inducer). S1 = 
duodenum; S2-S7 = jejunum; S8 = ileum. Liu et al., 2006 
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Figure 3.28.  Simulations (using Model A) examining the effect of changes 
in P-gp and CYP3A expression throughout the intestine. 
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Figure 3.29.  Comparison of the effect of changes in P-gp efflux activity on 
parameters used to quantify the interaction between P-gp and CYP3A in 
intestine.  Model A was used for simulations. 
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Figure 3.30.  PK Model B. Four-compartment pharmacokinetic model 
describing the interaction between P-gp efflux and CYP3A-mediated 
metabolism of dual substrates in the intestine.   
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Figure 3.31. Simulation of the effect of increased P-gp efflux on 
amount of metabolites formed over time using Model B. kba 
represents the first-order rate constant for P-gp efflux. 
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CHAPTER 4: DISCUSSION AND 
CONCLUSIONS
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A. INTRODUCTION 
 
The CYP subfamily most commonly involved in drug-drug interactions is CYP3A 
because of its wide substrate specificity (Bu, 2006) and large interindividual and 
intraindividual variation in hepatic (Shimada et al., 1994) and intestinal (Paine et al., 
1997) expression.  While hepatic CYP3A has been implicated in drug-drug 
interactions for many years (Kristensen, 1976), the pioneering work by Watkins et al. 
(Watkins et al., 1991) demonstrated that CYP3A is also expressed in the intestinal 
epithelium and that it plays a significant role in drug-drug interactions.  Generally, the 
expression of CYP3A is highest in upper small intestine and decreases distally 
(Paine et al., 1997).    During absorption of an orally administered drug, a significant 
percentage of the dose could be metabolized by CYP3A, both in the intestine and in 
the liver, before the drug reaches the systemic circulation.  This so called “first-pass 
metabolism” reduces the availability of the administered dose (exposure) of the drug 
to the systemic circulation.  Thus, intestinal CYP3A could contribute significantly to 
drug-drug interactions when two or more CYP3A substrates are co-administered 
orally.   
 
The efflux transporter P-gp (and the related transporter BCRP), expressed in the 
apical membrane of enterocytes, is recognized as another important biochemical 
barrier that can influence the rate and extent of absorption of orally administered 
drugs.  P-gp efflux is now recognized as a cause of intestinal drug-drug interactions 
(Endres et al., 2006).  Due to the large overlap in substrate specificity between CYP3A 
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and P-gp, some drug interactions previously attributed to CYP3A have been shown 
to be at least partially due intestinal P-gp, which can be a rate-limiting factor in 
absorption (Lown et al., 1997).  The pharmaceutical industry has therefore begun to 
implement in vitro assays to detect interaction of drug candidates with P-gp (Polli et 
al., 2001). 
 
Although metabolism and efflux are often separately assessed using in vitro 
models, these processes may not occur independently in vivo.    The concept that P-
gp-mediated efflux of a compound may influence its metabolism if the compound is 
also a substrate for a metabolic enzyme in the intestinal epithelium has evolved over 
the past few years (Johnson et al., 2003b; Tam et al., 2003; Cummins et al., 2004).  This 
interaction could be important for many compounds, as there is significant overlap in 
the specificities of P-gp and CYP3A.   
 
B. PROJECT STRATEGY 
  
 While the potential for interaction between P-gp and CYP3A in intestine is 
well recognized, there is little consensus regarding the nature of the interaction or its 
implications for drug delivery.  There is some evidence that P-gp efflux could 
increase the extent of CYP3A-mediated metabolism in the intestine.  Most of the 
work done to date has used in vitro models (e.g., Caco-2) to reach this conclusion 
(Cummins et al., 2002; Cummins, et al., 2004).  However, other groups have used 
pharmacokinetic modeling to show that P-gp efflux is unlikely to enhance the rate or 
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extent of metabolism since metabolic and efflux processes compete with each other 
(Tam et al., 2003; Johnson et al., 2003).  Therefore, more work is needed in this 
area to bridge the gap between the theory and experimental in vitro results. 
 
 In this work, the question of P-gp/CYP3A interactions was addressed in a 
unique fashion.  Two in vitro models, an immortalized cell line and fresh intestinal 
tissue from a preclinical model, were used to examine the mechanism behind the P-
gp/CYP3A interaction.  Comparison of data from the two model systems allowed for 
enhanced data interpretation and model evaluation.  While cell lines have frequently 
been used to study this phenomenon, previous studies have not addressed the 
concentration-dependence of the interaction.  Therefore, in this work, a large range 
of dosing concentrations was used in order to more closely examine the effect of 
concentration and to attempt to extrapolate the results to in vivo predictions.  
Pharmacokinetic modeling was used to analyze the results and to extend them to 
hypothetical in vivo situations.  
 
B.I. Caco-2 Cell Model 
 
One model that has recently been developed to address the interaction between 
efflux transporters and drug metabolizing enzymes in intestine is the CYP3A-
expressing Caco-2 cell model.  Caco-2 is an immortalized cell line that is derived 
from human colon carcinoma cells.  This cell line is already widely used for 
assessment of compound permeability and susceptibility to P-gp efflux.  It has very 
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low constitutive CYP activity, but it has been adapted to express CYP3A.  One 
method of inducing CYP3A expression is treatment with 1α, 25-dihydroxyvitamin D3 
(Schmiedlin-Ren et al., 2001; Mouly et al., 2004).  Other groups have used Caco-2 cells 
transfected with the CYP3A gene (Raeissi et al., 1999; Cummins et al., 2004).  Both 
methods produce Caco-2 cells that express functional CYP3A as well as levels of P-
gp that are comparable to levels in the human intestine.  P-gp is expressed on the 
apical membrane, while CYP3A is expressed in the endoplasmic reticulum.  This 
system allows for in vitro study of both efflux and metabolism, as well as their effects 
on each other.   
 
 While such cellular models are generally good for acquiring mechanistic 
information due to their simplicity, there are also certain limitations associated with 
their use.  One problem with these assays is their reliance on chemical inhibitors to 
modulate P-gp activity, since most of the available inhibitors of transporters have 
nonspecific effects (Achira et al., 1999).  For example, the P-gp inhibitor GW918 has 
also been shown to inhibit BCRP (Hyafil et al., 1993; Allen et al., 1999);  it has also 
been implied that GW918 inhibits a basolateral excretion mechanism in rat 
hepatocytes (Hoffmaster et al., 2004).  A key limitation of using a human-derived in 
vitro model, such as Caco-2 cells, to elucidate cellular disposition of drugs is that it 
requires well-designed clinical studies to assess whether those findings would be 
valid in a clinical setting.  While this is the ultimate objective of mechanistic in vitro 
studies, when there is lack of correspondence between the in vitro and clinical 
results, it is difficult to dissect what specific feature of the in vitro model needs to be 
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refined.  In contrast, an in vitro model based on a preclinical species, e.g. mouse or 
rat, would allow iterative evaluation of the predictions of the in vitro model model in 
an appropriately designed in vivo model until the predictions of the in vitro model 
have been validated in the in vivo system.  Refinement of the working in vitro model 
with input from a preclinically-derived in vitro/ex vivo model can provide better 
extrapolation to the clinic.   
 
In this work, the Caco-2 cell model was used, in tandem with a secondary 
(preclinical ex vivo) model, in order to produce results that could be examined in the 
context of the current literature and also to facilitate data interpretation.  While use of 
a chemical inhibitor was necessary to modulate P-gp activity in the Caco-2 cell 
model, appropriate controls were added to look for nonspecific effects.  For example, 
the effect of GW918 on the metabolism of testosterone, a CYP3A probe substrate 
that is not a substrate of P-gp, was determined in order to ensure that GW918 does 
not inhibit CYP3A directly.  In combination with a second model in which P-gp 
activity was modulated by genetic, rather than chemical, approaches, the results 
from the Caco-2 cell model were easier to evaluate, interpret and extrapolate to the 
clinical setting. 
. 
 
B.II. Diffusion Chamber Model 
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The P-gp-deficient mouse is a relevant model for studying the effect of P-gp 
efflux on metabolism.  Since this model expresses no functional P-gp, the intestinal 
CYP3A-mediated metabolism of dual substrates can be compared between this 
strain and the P-gp competent strain to determine the effect of P-gp efflux on 
metabolism. However, using in vivo experiments to examine intestinal metabolism is 
very difficult in this small animal, since the portal vein or mesenteric artery must be 
cannulated in order to avoid the confounding effects of drug metabolism and 
transport in the liver. Therefore, fresh mouse intestinal tissue mounted in side-by-
side diffusion (Ussing) chambers (Figure 2.1) provides a new ex vivo method for 
examining the metabolism/efflux interaction in a system that is closer to 
physiological conditions than cell lines.  Since intestinal tissues remain metabolically 
active for at least 3 hours in Ussing chamber (van de Kerkhof et al., 2006), a 
sufficient amount of metabolites can be generated for LC-MS/MS detection using 
this model.  Another important advantage of this system is that the results can be 
directly related to in vivo results in the same species (Collett et al., 2005).  Information 
derived from this in vitro-in vivo correlation can then be used to further refine current 
in vitro models to more accurately reflect the in vivo situation. 
 
There are some caveats to using the diffusion chamber model.  First of all, unlike 
the Caco-2 cell system, this method is labor-intensive and therefore not amenable to 
high-throughput.  Also, intestinal tissue in the side-by-side diffusion chamber system 
generally has about 10-fold higher paracellular permeability (assessed using 
mannitol) than the Caco-2 cell model.  This may be due to the stretching of the 
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intestinal tissue, which could expose not only the villus tips, but also the crypt 
surface area for absorption.  The villus tips have small pores (radius, <6 Å) while the 
less developed cells in the crypts have larger pores (50-60 Å) (Fihn et al., 2000).  Due 
to the increased permeability, P-gp appears to have a decreased effect in Ussing 
chamber (Gotoh et al., 2005).  These limitations must be kept in mind when using 
this model. 
 
Species differences must also be recognized when using an animal model.  The 
predominant CYP3A isoforms expressed in mouse intestine are CYP3A11, 
CYP3A13, CYP3A25 and CYP3A41.  CYP3A13 has the highest expression; in 
duodenum, its expression even exceeds that in the liver (Martignoni et al., 2006).  In 
addition to CYP3A, activities of CYP2E, CYP2D and CYP2C have been 
demonstrated in mouse intestinal microsomes (Emoto et al., 2000).  Although the 
enzymes expressed in mouse generally mirror those in human intestine, it must be 
kept in mind that the expression patterns and substrate specificities of these 
enzymes can differ substantially between species. 
 
Using two different models to examine the CYP3A/P-gp interaction allowed 
evaluation of each model relative to the other.  Although the Caco-2 cell model 
exhibited a larger “P-gp effect” (efflux ratio) than the mouse model, it turned out to 
be less sensitive to the effect of P-gp on metabolism.  Use of two different models 
also allowed closer examination of species differences between mouse and human.  
As discussed below, the results were not entirely consistent between the models 
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and the differences observed may be due to species differences, the properties of 
the compounds studied, and the sensitivity of the models themselves.  However, the 
differences between models contributed to a better understanding of the interactions 
between P-gp and CYP3A. 
 
B.III. Compounds 
 
     The Biopharmaceutical Classification System (BCS) was designed to help the 
FDA determine under what circumstances in vitro permeability studies could be used 
in lieu of clinical bioavailability studies to demonstrate bioequivalence for immediate-
release dosage forms.  This system categorizes drugs into four classes based on 
their solubility and permeability values (Amidon et al., 1995).  Class I drugs (e.g., 
acetaminophen) have high solubility and high permeability; Class II drugs (e.g., 
indinavir) also have high permeability, but have low solubility; Class III drugs (e.g., 
atenolol) have low permeability and high solubility and Class IV drugs (e.g., 
furosemide), have low permeability and low solubility.  Benet proposed that this 
classification of compounds based on their permeability and solubility also 
differentiates these compounds with respect to their likely interactions with 
uptake/efflux transporters, and even metabolic enzymes (Wu and Benet, 2005).  Class 
I drugs are expected to enter the cells readily via passive diffusion, and could easily 
saturate efflux transporters and metabolic enzymes; thus, their absorption is not 
likely to be affected by efflux transporters or first-pass metabolism.  Class II drugs 
enter the cells via passive diffusion, but might not achieve high membrane or 
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intracellular concentrations because of their low solubility.  Hence, these compounds 
are often affected by efflux transporters, and are subject to first-pass metabolism.   
Class III and IV compounds, with their low permeability, are likely to be absorbed via 
absorptive transporters and are less likely to be affected by first-pass metabolism. 
        
Two compounds, terfenadine and loperamide, were used in this work to study the 
interaction between P-gp and CYP3A.  These compounds, besides being dual 
substrates for P-gp and CYP3A, belong to BCS Class II (high permeability, low 
solubility), and therefore efflux and metabolism in the intestine play a significant role 
in their absorption.  Further, because of their high (passive) permeability, absorptive 
transporters are unlikely complicate interpretation of their transport behavior.  In 
addition to their permeability and solubility properties, an important parameter that 
was used for their selection as test compounds was the sensitivity of their absorptive 
transport to P-gp-mediated efflux, as measured by the parameter AQ (Troutman and 
Thakker, 2003).  AQ represents the degree to which the absorptive permeability of a 
compound is affected by P-gp efflux.  The AQ value of loperamide is 0.6 and the AQ 
of terfenadine is 0.4; therefore, P-gp attenuates loperamide’s absorptive transport by 
60%, and terfenadine’s transport by 40%.  While compounds with greater separation 
of AQ values would have provided greater dynamic range to study the effect of P-gp 
on metabolism, compounds with their AQ values at extreme ends of the (0-1) range 
might have posed analytical challenges with respect to the measurement of the 
substrate and/or metabolites.  Hence, for the first study of this kind, it was decided to 
use two compounds with medium but distinctly different extents of P-gp-mediated 
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attenuation in their absorptive transport.  During the course of the project, it became 
clear that the metabolism of terfenadine is also different than loperamide metabolism 
in that terfenadine, but not loperamide, is metabolized by other enzymes besides 
CYP3A in mouse.  Using compounds with different properties, such as AQ and the 
Michaelis-Menten parameters Vmax and Km, allowed for examination of the effect of 
these factors on the CYP3A/P-gp interaction.  
 
Designing these studies required not only careful selection of compounds but 
also selection of appropriate dosing concentrations.  One problem with assays that 
assess transporter/metabolism interplay is that they are generally conducted at only 
one dosing concentration (Cummins et al., 2002), which makes extrapolation to 
prediction of in vivo outcomes more difficult.  Since both P-gp and CYP3A are 
saturable, the interaction between the proteins would be expected to be 
concentration-dependent.  Therefore, all of the Caco-2 cell and diffusion chamber 
studies reported here were carried out over a broad range of substrate 
concentrations in order to determine the effect of concentration on experimental 
outcome.  However, the range was limited at the lower end by the detection limit of 
the metabolites and at the upper end by both cellular toxicity and solubility of the 
compound.  The compounds used were sparingly soluble in aqueous solution, so the 
maximum concentration used was about 100 µM.  At the highest dosing 
concentrations, a larger standard deviation was observed for the metabolic data.  
This variability probably reflects the instability of the solution system 
(precipitation/crystallization) rather than variability in the interactions of the 
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compounds with their target proteins.  While this variability imposed limitations on 
establishing clear statistical significance to the results obtained at the upper end of 
the concentration range, it added value by allowing the observation of the 
interactions between P-gp and CYP3A over a wide range of substrate 
concentrations. 
 
C. DISCUSSION OF RESULTS 
 
C.I. Studies with the Caco-2 Cell Model 
 
For both loperamide, there was a significant difference (two-way ANOVA) in 
the metabolic profiles in the presence and absence of P-gp inhibition.  The metabolic 
rate increased when P-gp was inhibited by GW918.  The increase in metabolic rate 
was relatively small at low concentrations, but became quite significant (>2-fold) in 
the 10-20 µM concentration range; this increase in metabolic rate was presumably 
caused by an increase in steady-state intracellular concentrations in the absence of 
P-gp.  At concentrations approaching 40 µM, the rate of metabolism appeared to 
plateau, and at the same time the increase in metabolism due to inhibition of P-gp 
declined.     This resulted in a two-fold higher apparent Km in the presence of efflux.  
Nonlinear regression analysis showed this difference to be statistically significant, 
while there was no statistical difference in Vmax, although the ability to accurately 
determine the Vmax was limited due to increased variability at high dosing 
concentrations (presumably reflecting instability of compound in solution due to the 
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proximity to the solubility limit).  These results clearly illustrate the value of 
examining the interactions between P-gp and CYP3A over a wide concentration 
range.  Whether this interaction will be significant for loperamide in a clinical setting 
may depend on the dose; if the dose achieves cellular/membrane concentrations of 
20-40 µM, the interactions could be significant. 
  
A commonly used parameter for quantifying the transport/metabolism 
interaction in intestine is the ER (Equation 1).  As shown in Figure 4.1, despite the 
higher rate of metabolism in the presence of P-gp inhibitor, the ER for loperamide 
decreased (30% for the 20 µM dose).  This is because the amount of metabolite 
formed is normalized to the amount of parent crossing the cell monolayer, which 
always increases with P-gp inhibition regardless of changes in metabolic rate.  
Clearly extraction ratio, as it has been defined (Cummins et al., 2002), is not an ideal 
descriptor for quantifying the effect of P-gp on the rate or extent of metabolism of a 
compound.  If it were used as such, it would indicate that metabolism of loperamide 
decreased when P-gp was inhibited, a conclusion that is contrary to the observed 
results.  The reason why the use of ER as a parameter to describe the effect of P-gp 
on metabolism could be misleading is that the effect of P-gp on the permeability of 
the parent is embedded in the definition. Since the permeability of the parent is 
decreased by P-gp, the increase in metabolism is masked, and often this leads to 
the false conclusion that inhibition of P-gp results in a decrease in metabolism and 
therefore that P-gp causes an increase in metabolism.  Therefore, it is inappropriate 
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to use the ER to interpret these results, since this would lead to erroneous 
conclusions.  
 
Similar to the result for loperamide, the calculated ER values for terfenadine 
decreased in the presence of inhibitor; however, dissimilar to loperamide, the rates 
of metabolism were unchanged.  There could be several reasons why the results 
observed for terfenadine in the Caco-2 cell model are different from those seen for 
loperamide.  First of all, the difference in AQ between the two compounds 
(terfenadine AQ = 0.4; loperamide AQ = 0.6) suggests that the absorption of 
loperamide is affected more by P-gp efflux than is the absorption of terfenadine.  
That is, P-gp decreases the absorption of terfenadine and loperamide by 40% and 
60%, respectively.  Therefore, P-gp would be expected to have more of an effect on 
intracellular concentrations of loperamide than terfenadine, and therefore more of an 
effect on metabolism.  Secondly, terfenadine (and also its metabolite fexofenadine) 
appears to be affected by other (possibly MRP family) transporters besides P-gp in 
the Caco-2 cell system.  Therefore, treatment with P-gp inhibitor may not have been 
able to fully inhibit efflux of the compound.  More importantly, based on the intrinsic 
metabolic parameters measured in human intestinal microsomes, the intrinsic 
metabolic clearance (Vmax/Km) of loperamide is about 10-fold higher than that for 
terfenadine in human.  In addition, the expression of CYP3A in Caco-2 cells as a 
result of the 1α,25-dihydroxyvitamin D3 treatment is rather modest, leading to lower 
intrinsic metabolic clearance.  As illustrated in Figure 3.28, the effect of P-gp on 
metabolism would be expected to be dampened at lower intrinsic clearance values.  
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A combination of these factors is likely to be responsible for the lack of P-gp effect 
on CYP3A-mediated metabolism of terfenadine in the Caco-2 cell system. 
 
C.II. Mouse Intestinal Model Results 
 
Unlike the results seen in the Caco-2 cell model, in mouse intestine a 
statistical difference (using two-way ANOVA) in overall metabolic rate in the 
presence versus absence of P-gp efflux was seen for both terfenadine and 
loperamide.  At low dosing concentrations, the rates of metabolism were not 
distinguishable between the strains due to the variability of the assay.  However, in 
the dosing range near the Km value for metabolism, the rates of metabolism were 2-
3 fold higher in the absence of P-gp efflux, which supports the hypothesis that P-gp 
efflux decreases metabolism in the intestine (Tam et al., 2003).  At higher 
concentrations, the effect was saturated and the metabolic rates were nearly equal 
for the two strains.  A higher degree of variability was also observed in this region of 
the profile (near the solubility limit) due to instability of these compounds in aqueous 
solutions. 
 
Based on studies using intestinal microsomes, the intrinsic metabolic 
clearances of loperamide and terfenadine are more similar in mouse than in Caco-2 
cells, so Figure 3.28 would predict similar results for the two compounds.  Indeed, a 
decrease in metabolic rate in the presence of P-gp efflux was observed for both 
compounds in the mouse model. When the curves were simultaneously fit for the 
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two strains of mice, the apparent Km values were higher in the P-gp competent mice 
(about 5-fold higher for loperamide and 4-fold higher for terfenadine).  These results 
imply that, while the intrinsic metabolic parameters are the same between the two 
strains of mice, the apparent Km is inflated in the P-gp competent mice because the 
intracellular concentrations are reduced in the presence of P-gp efflux.  Therefore, at 
intestinal concentrations close to the Km, a higher dose of terfenadine would be 
required in the P-gp competent mouse to produce an equivalent concentration of 
drug at the enzyme site and the corresponding amount of metabolites.   
 
 For loperamide, the increase in Km due to P-gp efflux was about 5-fold.  This 
is much higher than the 2-fold increase seen in the Caco-2 cell system.  This implies 
that the mouse model is more sensitive to the effect of P-gp efflux on metabolism 
than the Caco-2 cell model.  This may be partly due to the higher intrinsic metabolic 
clearances of the tissues relative to the cell system.  Since terfenadine showed a 
much higher metabolic clearance in mouse tissue relative to the Caco-2 cell model, 
this could further help to explain the different effects observed for terfenadine in the 
two models. 
 
Differences in the results from the two model systems for terfenadine led to 
more mechanistic studies examining species differences in terfenadine metabolism.  
Studies using intestinal microsomes from mouse and human showed differences in 
the extent of metabolism (per mg protein) of probe substrates for several CYP 
enzymes.  CYP3A activity was about 1.5-fold higher in mouse than in human, while 
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CYP2C9 activity was 3-fold higher in human than the activity of the analogous 
enzyme in mouse.  The largest difference in activity was observed for CYP2D: the 
activity was about 25-fold higher in mouse than in human intestinal microsomes.  
Besides differences in metabolic capacity, other species differences between mouse 
and human were revealed through these experiments.  While the metabolism of 
loperamide was similar in the two species, the Km values for terfenadine varied 
substantially between species (Table 3.1).  Further investigation revealed that 
terfenadine is metabolized primarily (~60%) by a member of the CYP2D family in 
mice.  This may be due to the high relative level of activity of CYP2D in mouse 
intestine.  This could help account for the different results observed between Caco-2 
cells and mouse intestinal tissue for terfenadine, as terfenadine is metabolized only 
by CYP3A in Caco-2 cells, since this is the only isoform known to be induced by 
Vitamin D3 treatment.  Therefore, Caco-2 cells may have limited metabolic capacity 
for terfenadine relative to mouse tissue, leading to less of an effect of P-gp on 
metabolism in the Caco-2 cell model. 
 
One of the key findings of this work is that concentration is an important 
consideration when examining the interactions between efflux and metabolism.  
Although a decrease in metabolism due to P-gp efflux was observed for loperamide 
in Caco-2 cells and mouse tissue as well as for terfenadine in mouse tissue, this 
effect was only seen within a narrow concentration range near the Km value.  At 
higher concentrations, such as those likely to be seen in the proximal intestine after 
oral dosing, this interplay may not have any effect on absorption.  Therefore, the 
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anticipated concentration in the gut, relative to a drug’s kinetic parameters, must be 
considered when determining the net effect of efflux and metabolism on a given 
substrate. 
 
 For example, the clinical dose prescribed for terfenadine was 60 mg.  
Assuming a volume of 250 ml in the gut, the calculated maximum concentration of 
terfenadine would be 500 µM.  Therefore, terfenadine would likely be at a 
concentration near its solubility limit (~100 µM or higher, depending on the 
solubilizing effect of bile acids) in the intestine.  According to the results reported 
here, the P-gp/CYP3A interaction would most likely be insignificant for terfenadine in 
intestine, since the process would always be saturated.  Conversely, for loperamide, 
we may expect to see the interaction in vivo.  The clinical dose of loperamide is only 
2-4 mg, resulting in a predicted maximum concentration of only 33 µM in vivo.  At 
this concentration level, the in vitro model presented here predicts an interaction 
between P-gp and CYP3A resulting in a decrease in metabolic rate.  It should be 
kept in mind, however, that this crude method of calculating gut concentrations of 
compounds may not accurately reflect the concentration of the physiological 
microenvironment near the transporter or enzyme.  Factors such as the unstirred 
water layer and mucous secretion may also influence the effective concentrations in 
the microenvironment. 
 
When assessing this interaction for a given compound, the following three 
questions should be asked:  1) Is the compound a good substrate for P-gp?  This 
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can be assessed in vitro using cellular models such as MDCK-MDR1 or Caco-2 
cells.  AQ should be determined to assess the effect of P-gp on the compound’s 
absorption.  2)  Does the compound have high metabolic clearance in intestine 
(does it have a high fraction metabolized)?  Intestinal microsomes would be a good 
model to use in answering this question.  3)  Is the compound poorly soluble or will it 
be administered at a low dose?  Low-solubility and low-dose compounds would be 
much more likely to exhibit an interaction between P-gp and CYP3A in vivo: since 
concentrations at the transporter would be low, the effect of P-gp would be less likely 
to saturate.  If the answer to all of these questions is “yes”, then more study of the P-
gp/CYP3A interaction may be warranted for the compound.  Studies such as the 
ones described in this work would be appropriate if performed over a large 
concentration range.  Of the two models used, mouse model seems to provide a 
more sensitive test for the interaction.  However, more studies should be done in this 
area, using compounds with wider range of AQ values and kinetic parameters for 
metabolism, before a definitive in vitro-in vivo correlation model can be developed. 
 
Ideally, compounds with a larger range of AQ (i.e., with a range of susceptibility 
to P-gp efflux) would have been used for these studies.  Since AQ can have a value 
anywhere between 0 and 1, using substrates with very low and very high AQ values 
would provide the maximal dynamic range for these experiments.  However, since 
no effect of P-gp efflux on CYP3A-mediated metabolism was observed for 
terfenadine (AQ~0.4) in the Caco-2 cell model, this AQ value may represent a cutoff 
at which no effect of the P-gp/ metabolism interaction is observed.  In other words, a 
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substrate with a very low AQ would be marginally affected by P-gp efflux, so the 
effect of efflux on metabolism would likely be too low to detect.  Conversely, 
compounds with very high AQ would be difficult to use for these studies, since the 
permeability would be so low that very little compound would reach the cellular and 
basolateral chambers, and therefore very little metabolite would be produced, 
leading to problems with analytical detection.  As a result of these limitations, the 
range of AQ for the compounds selected for these studies was only 0.4-0.6, yet the 
differences observed in the results for these two compounds imply that this range 
was probably sufficient to differentiate between the effects of P-gp on CYP3A-
mediated metabolism for compounds of differing AQ values.  For future studies, 
additional compounds should be analyzed with a wider range of P-gp effect on 
absorption, physicochemical properties (solubility, permeability), and metabolic 
parameters (Km, Vmax) to define the interactions between P-gp and CYP3A-mediated 
metabolism more rigorously and under wider physiological conditions. 
 
C.III. Pharmacokinetic Modeling Results 
 
Due to the large overlap in substrate specificity between CYP3A and P-gp, some 
drug interactions previously attributed to CYP3A have been shown to be caused at 
least partially by intestinal P-gp, which can be a rate-limiting factor in absorption 
(Lown et al., 1997).  Although metabolism and efflux are often separately assessed 
using in vitro models, these processes probably do not occur independently in vivo.  
Therefore, complex models, or a better understanding of the implications of data 
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generated using current models, may be needed to evaluate the drug-drug 
interaction potential of a given compound. 
 
Here, pharmacokinetic modeling was used to more fully understand the in 
vitro results obtained for terfenadine and loperamide, and also to make predictions 
for compounds with different properties.  A simple three-compartment 
pharmacokinetic model (Model A) was able to adequately describe the data 
generated from terfenadine metabolism in the Caco-2 cell system.  Simulations were 
then carried out using this model in order to predict the effect of P-gp efflux on 
CYP3A metabolism under different conditions (i.e., for compounds with differing 
degrees of efflux and metabolism).  While the experimental studies provide data on 
the activity of CYP3A in the presence and absence of P-gp efflux, modeling studies 
can predict the effect of varying degrees of P-gp activity on metabolic rate.  The 
model predicted a decrease in the rate of metabolism with increasing P-gp efflux.   
 
Simulations were also performed in order to determine the effect of changing P-
gp or CYP3A expression levels.  Since CYP3A is known to be expressed to a 
greater extent in the proximal intestine, while P-gp expression is higher in the distal 
regions, the effect of P-gp on CYP3A-mediated metabolism can vary throughout the 
intestine.  The results from these simulations indicate that the effect of P-gp on 
metabolism would be expected to decrease in the distal areas of intestine as CYP3A 
expression decreases and P-gp expression increases.     
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Another finding revealed by these simulations was that, since P-gp modulates 
the metabolism distally, a change in Vmax (such as that observed with 
noncompetitive inhibition) would have less of an effect on metabolic rate in this 
region.  That is, the percent change in metabolism due to inhibition of the enzyme 
would be less than expected.  In other words, P-gp may be able to effectively reduce 
the impact of inhibition when the mechanism is not competitive.  Conversely, at 
lower values of Vmax, the effect of P-gp efflux on metabolism would be predicted to 
be reduced.  This is consistent with the difference in results observed for terfenadine 
and loperamide in the Caco-2 cell model, as was discussed earlier.  According to the 
model, the lower intrinsic metabolic clearance for terfenadine translates into a 
reduced effect of P-gp on metabolism. 
 
Finally, the different parameters used to quantify the interaction between CYP3A 
and P-gp in intestine were compared.  The ER, a commonly used parameter for 
describing the P-gp/CYP3A interaction, increased with increased P-gp efflux, even 
though the metabolic rate and percentage of dose metabolized remained relatively 
constant.  If these parameters were applied to the results for terfenadine in Caco-2 
cells, there would be no change in percent metabolized with P-gp inhibition, but ER 
would decrease.  This could lead to the conclusion that P-gp efflux increases the 
extent of terfenadine metabolism, but this is an artifact.  The results of these 
simulations confirm that the use of ER to determine the nature of the interaction 
between P-gp and CYP3A may be misleading, as has been previously suggested 
(Johnson et al., 2003a; Knight et al., 2006).  Therefore, caution should be used in 
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choosing parameters to quantify this interaction.  The percent of dose metabolized 
(or rate of metabolism) seems like a more relevant value for quantifying this 
interaction, since the effect of P-gp efflux on absorption is not incorporated into this 
parameter. 
 
Although Model A produced some interesting results, it should be recognized that 
this model may be oversimplified in that it assumes P-gp and CYP3A to be acting on 
the same (cytosolic) compartment.  However, this is the most complex model that 
could be developed based on the data acquired.  A second, more theoretical model 
(Model B) was written which incorporated an additional compartment (ostensibly 
representing the apical membrane) for P-gp efflux.  Simulations of the effect of P-gp 
efflux on metabolic rate were carried out using this model, and the result was similar 
to those obtained with Model A.  An increase in P-gp efflux resulted in a predicted 
decrease in metabolic rate, as was observed with Model A, but it also resulted in an 
increased lag time for metabolism.  It appears that incorporation of a separate 
compartment for P-gp can increase the time it takes for the substrate to reach the 
CYP3A enzyme. 
 
D. LITERATURE CONTEXT FOR FINDINGS OF THIS DISSERTATION RESEARCH 
 
Several conflicting reports have been published that articulate the interaction 
between P-gp and CYP3A during intestinal absorption of dual substrates using 
different parameters; this has caused considerable confusion regarding the effect P-
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gp-mediated efflux has on CYP3A-mediated metabolism.  Pharmacokinetic theory 
predicts that P-gp efflux would decrease intracellular concentrations of parent drug, 
thereby decreasing metabolite formation.  In spite of this, studies done in cellular 
models have led some researchers to the conclusion that P-gp efflux may enhance 
metabolism of substrates.  This theory is primarily based on the observation that P-
gp inhibition decreased the extraction ratio (ER) of substrates in cellular models.  
The ER has been defined as follows (Fisher et al., 1999): 
∑
∑
+
=
outsmetabolite
smetabolite
MM
M
ER          Equation 1 
 
Where Mmetabolites = mass of metabolites in the apical, cellular, and basolateral 
compartments and Mout = mass of parent in the basolateral chamber.  Some 
researchers also include the mass of the parent within the cell in the calculation for 
Mout (Benet et al., 2004).  However, as recently noted (Knight et al., 2006), this ratio 
by definition decreases in the presence of a P-gp inhibitor, since the denominator 
increases when P-gp inhibition increases the flux and intracellular concentrations of 
the parent drug.  Therefore, changes in this parameter may not necessarily be 
indicative of changes in metabolic rate since the effect of P-gp on absorption is 
incorporated into the ER.   
 
For example, Hochman, et al. reported that the extent of indinavir metabolism 
was not affected by inhibition of P-gp with cyclosporine A in the Caco-2 cell system.  
However, by using the ER (normalizing the amount of metabolite produced to the 
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amount of parent transported), the authors concluded that inhibition of P-gp efflux 
decreases metabolism (Hochman et al., 2000).  
 
 Also using the Caco-2 cell system, Cummins et al. reported that the ER for the 
cysteine protease inhibitor K77 decreased from 0.33 to 0.14 in the presence of P-gp 
inhibitor (Cummins et al., 2002).  These results could possibly be explained by the fact 
that K77 has been shown to inhibit CYP3A with an IC50 of 60 nM (Jacobsen et al., 
2000).  When P-gp is inhibited, intracellular concentrations of drug would increase, 
causing inhibition of CYP3A and confounding the effect of P-gp on metabolism. 
However, examination of the data shows that the amount of metabolites produced 
actually increased slightly, so the percentage of dose metabolized increased.  The 
use of ER in these studies led to the conclusion that P-gp increases the extent of 
metabolism, when in reality the amount of metabolites formed was lower in the 
presence of P-gp efflux.  This illustrates the point that the rate of metabolism and 
percent metabolized are more relevant parameters for examining 
transport/metabolism interactions, since use of these parameters to interpret the 
data would lead to the appropriate conclusion that P-gp decreased the extent of 
metabolism.  In a subsequent study, the same group showed that the ER of 
sirolimus decreased 25% in the presence of P-gp inhibitor (Cummins et al., 2004).  
The amount of metabolites produced was not reported, so the percentage of dose 
metabolized cannot be estimated.   
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Another group used the dual substrate saquinavir to study the interaction 
between P-gp and CYP3A (Mouly et al., 2004).  Unlike the previously described 
studies, this study was done at multiple dosing concentrations to examine the effect 
of concentration on the interaction.  The authors were able to show that the ER 
decreased with P-gp inhibition, but also decreased with increasing dose.  This 
illustrates the importance of differentiating the linear from nonlinear range of 
metabolism when performing these studies.  Since P-gp inhibition increases the 
amount of parent drug within the cell, at certain concentrations this could lead to 
saturation of the enzyme and a corresponding decrease in the ER. 
 
In order to correctly interpret these types of results, the rate of metabolism must 
be considered in addition to the total mass of metabolite produced. As discussed 
earlier, the rate of metabolism and percent of dose metabolized are more relevant 
parameters than ER for examining the ultimate effect of efflux on metabolism.   In 
Chapter 3, the effects of changes in P-gp efflux on ER and percent metabolized 
were compared through a simulation exercise.  As can be seen in Figure 3.29, ER 
increases with an increase in P-gp activity, while percent metabolized only slightly 
decreases.  Clearly, use of this metric (ER) to determine the effect of efflux on 
metabolism would be confounded by changes in parent disposition due to efflux 
itself.  Therefore, the rates of metabolism and the percent of dose metabolized 
should be used instead of ER to interpret the results of these types of studies. 
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One of the theories about the interaction between efflux and metabolism 
suggests that P-gp efflux synergistically enhances metabolism through repeated 
cycles of drug entering the cell, being partially metabolized, and being effluxed back 
into the intestinal lumen.  However, this “recycling hypothesis” is inconsistent with 
what is known about the mechanism of P-gp efflux.  Since the active site of P-gp has 
been localized to the apical membrane, drug molecules need not enter the 
cytoplasm before being subject to efflux by P-gp (Figure 4.2).  In fact, many of the 
substrates of P-gp are lipophilic in nature and are therefore likely to accumulate in 
the membrane.  There is also further evidence for this mechanism.  The fluorescent 
probe fura-2 acetoxymethyl ester (a P-gp substrate) is hydrolyzed by esterases to its 
free acid (a non-P-gp substrate) within cells. NIH-3T3 mouse fibroblasts expressing 
P-gp trapped less of the free acid than cells without P-gp, suggesting that the ester 
was able to be effluxed from the membrane before reaching the esterases within the 
cell (Homolya et al., 1993).  Similarly, the Calcein-AM assay for P-gp activity (Figure 
4.3) relies on the concept that hydrolyzed fluorescent compound is trapped in the 
cells to a lesser extent in the presence of P-gp efflux (Polli et al., 2001).  If the 
compound were being “recycled” in and out of the cell, it would be more extensively 
converted to its hydrolyzed form, which is not a P-gp substrate. 
 
Proponents of the theory that P-gp efflux enhances metabolism also assert that 
P-gp increases the ER by increasing the mean residence time (MRT) of the 
compound, therefore providing more opportunities for metabolism.  However, 
extensive pharmacokinetic modeling done by Tam et al. showed that, although MRT 
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can be increased due to P-gp efflux, the rate of metabolism was still decreased 
under linear conditions (Tam et al., 2003).  Under nonlinear conditions, however, there 
is a possibility for P-gp to increase metabolic rate by “desaturating” the enzyme; that 
is, by bringing the rate of metabolism back into the linear range.  The data presented 
in this dissertation support the conclusions derived from those modeling studies but 
also provide experimental results to support the hypothesis that P-gp efflux 
decreases the rate of CYP3A metabolism of dual substrates in the intestine.  The 
use of a wide range of dosing concentrations provides further insight into the in vivo 
relevance of this important interaction. 
 
E. FUTURE STUDIES 
 
E.1. Terfenadine Studies 
 
Overall, the probable involvement of other transporters and drug metabolizing 
enzymes in the absorption of terfenadine makes interpretation of the data more 
difficult.  For future studies, dual substrates should be more fully characterized (to 
rule out the involvement of transporters besides P-gp and metabolizing enzymes 
besides CYP3A) before being chosen for study of the P-gp/CYP3A intestinal 
interaction. 
 
Due to the complexity of its metabolism and transport, there are several 
additional studies that could be designed based on the work done using terfenadine.  
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Although the disposition and metabolism of terfenadine have been described here in 
some detail, several questions remain regarding its behavior in vivo.  For example, it 
is not clear whether terfenadine may be affected by other transporters besides P-gp.  
Since its uptake into Caco-2 cells was increased by treatment with the MRP inhibitor 
MK571, it seems likely that other apical efflux transporters are involved, possibly 
transporter(s) in the MRP family.  In addition, the involvement of as yet unidentified 
transport proteins that are subject to inhibition by MK571 cannot be ruled out.  The 
most common model used to clearly determine which transporters are affecting the 
compound is the singly-transfected MDCK cell system.  The permeabilities (A-to-B 
and B-to-A) of the compound can be measured in cells which express a single 
transporter and can then be compared to the permeabilities of the parent cell line.  
Differences in the permeabilities can then be attributed to a specific transporter.  
These experiments could therefore be done using MDCK cells which express MRP2 
on the apical membrane to determine whether MRP2 is important in the disposition 
of terfenadine. 
 
The metabolism of terfenadine by multiple P450 isoforms in intestine is another 
interesting area of study.  Until recently, terfenadine was thought to be strictly a 
CYP3A substrate.  However, terfenadine has clearly been shown to be a substrate 
for CYP2J (Patten et al., 2003).  Since CYP2J was relatively recently discovered, not 
much is known about its role in intestinal metabolism.  However, since CYP2J is 
expressed in intestine (Zeldin et al., 1997), it seems likely that its effect could be quite 
significant for some compounds.  Terfenadine has also been shown to be a 
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substrate of CYP4F12 (Patten et al., 2003) and CYP2D6 (Jones et al., 1998).  In this 
work, about 60% of the metabolism of terfenadine in mouse intestine was found to 
be mediated by CYP2D (presumably by CYP2D22, the mouse analog of CYP2D6), 
while the remaining 40% was mediated by CYP3A.   Although terfenadine is only 
used as a probe substrate, since it is no longer a marketed drug due to its 
cardiotoxicity, it could still be important to understand its properties if it is to be used 
for future mechanistic studies.  More importantly, since CYP2D6 is polymorphic in 
humans, an interaction between P-gp and CYP2D6 could have implications for drug-
drug interactions involving CYP2D6 substrates.  In intestine, the activity of CYP2D in 
human appeared to be substantially lower than that for mouse, so CYP2D6 
metabolism is not likely to be important in the first-pass intestinal metabolism of most 
compounds in humans.  However, CYP2D6 is known to be highly expressed in the 
brain (Miksys et al., 2002).  Since many CNS drugs (such as antidepressants) are 
metabolized by CYP2D6, perhaps there is even a possibility for interaction between 
drug transporters and CYP2D6 in the brain.  This would be a very interesting area 
for future studies.   
 
E.2. Studies with Different Dual Substrates 
 
Another important study that could stem from this research is the investigation of 
the metabolism/efflux interaction using additional substrates.  It would be desirable 
to choose CYP3A/P-gp dual substrates with different physicochemical or kinetic 
properties than those already examined.  In this way, the effect of additional 
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parameters, such as passive permeability, on the metabolism/efflux interaction could 
be examined.  It would be optimal to test compounds with a larger range of AQ 
values to determine the effect of varied P-gp influence on absorptive transport on the 
interaction, although, as discussed earlier, using compounds at the extremes of the 
range may not be practical.  It may also be interesting to compare substrates from 
BCS Classes II and III to determine which is more affected by this interaction.  It has 
been hypothesized that compounds in Class II would be more susceptible to these 
interactions (Wu and Benet, 2005); it would be interesting to test this hypothesis using 
the model systems described here.  The data presented here indicate that the types 
of compounds likely to be affected by this interaction would be high clearance, low 
solubility compounds.  If compounds with different properties were tested, the 
understanding of which properties affect the P-gp/CYP3A interaction would be 
expanded.  Ultimately, a model could be developed for prediction of the effect of this 
interaction on the disposition of new compounds. 
 
E.3. In vivo Studies 
 
Although in vitro data reveal important mechanistic information, they are basically 
derived from a static system.  The same types of studies performed here could be 
implemented in a whole organism, since it is a more dynamic system.  Therefore, 
the next step in testing the hypotheses presented here would studies in an 
appropriate in vivo model.  This would allow determination of the in vivo relevance of 
the in vitro results and would facilitate development of an in vitro/in vivo correlation.  
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This data could then be used to validate and refine current in vitro models.  If this 
information were gathered for several compounds, a model could begin to be 
developed for prediction of the in vivo effect of the P-gp/CYP3A interaction on the 
disposition of other compounds based on in vitro data alone.  In situ intestinal 
perfusion using P-gp-deficient and P-gp-competent mice would reveal whether the 
metabolism/efflux interaction is important in vivo.  Animals deficient in other transport 
proteins could also be used to study interactions between efflux and metabolism.  
For example, an mrp2 deficient mouse is available that could be used to study the 
relationship between glucuronidation and mrp2 efflux.  This information would be 
very useful for extrapolating in vitro results to predictions of the effect of the 
interaction in humans.     
     
A few in situ intestinal perfusion studies have been done in this area using rats 
and chemical modulation of P-gp.  Cummins et al. measured the metabolism of K77 
in the presence and absence of P-gp inhibitor GW918.  Inhibition of P-gp caused a 
marked increase in the amount of metabolite produced over time, so the percentage 
of dose metabolized increased.  While they reported a decrease in the ER with P-gp 
inhibition (from 0.60 to 0.49), this change was not statistically significant (Cummins et 
al., 2003).  Another group used the dual substrate verapamil to conduct a similar 
study.  They also reported an increase in the amount of metabolites formed in the 
presence of P-gp inhibitor, yet the ER decreased by 15% (Johnson et al., 2003b).  In 
each case, the conclusions drawn depend on the method of interpretation of the 
data.  The ER value includes the effect of P-gp inhibition (increased absorption) in 
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the equation and therefore cannot be used to assess the effect of P-gp efflux on 
metabolism alone.  Instead, rate of metabolism or the percent metabolized should be 
used to assess the effect of transport/metabolism interplay. 
 
Determining the clinical significance of the metabolism/efflux interaction is, of 
course, the ultimate goal of this work.  So, could a clinical study be designed to 
address the hypotheses detailed here?  If so, a relatively innocuous P-gp inhibitor 
and CYP3A/P-gp dual substrate would be needed for study in humans.  As with the 
rodent studies, a perfusion technique would be employed, similar to that used by 
Lennernas, et al. (Lennernas, 1997), to compare the metabolism of a dual substrate 
in the presence versus absence of P-gp inhibitor.   Systemic concentrations of 
metabolite could not be used to assess metabolism due to the confounding effects of 
the liver.  Therefore, blood would have to be collected before it enters the liver.  
However, it would probably not be feasible to collect samples from the portal vein or 
mesenteric artery in humans, so disappearance of parent would probably have to be 
used as a measure of metabolism.  Of course, parent disappearance is a function of 
absorption, efflux and metabolism, so this method may not be effective for studying 
the interaction between these factors.   
 
Metabolite formation could also be measured, but only within the lumen.  This is 
also problematic since, as shown in this work, metabolite disposition can change 
with P-gp inhibition.  For example, we noticed that fexofenadine is primarily secreted 
into the apical compartment when P-gp is active, but when P-gp is inhibited, 
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fexofenadine localizes to the basolateral compartment.  If only the apical 
compartment were being sampled, the decrease in fexofenadine in the presence of 
inhibitor may be misinterpreted as a decrease in metabolic rate due to P-gp 
inhibition.  Since it is not possible to sample all three compartments (apical, 
basolateral, and tissue), designing a clinical study to examine this issue is probably 
not feasible at this time.  Therefore, we must rely on studies in rodents and in vitro 
systems to provide information about the effect of P-gp efflux and metabolism in 
vivo. 
 
F. SUMMARY 
 
The interplay between P-gp efflux and CYP3A metabolism in intestine is an 
important area of research.  Most studies in this area have used the Caco-2 cell 
model at a single dosing concentration and the results have been interpreted using 
ER as a measure of the effect of P-gp on the extent of metabolism.  In this work, a 
second model has been used in addition to the Caco-2 cell model: metabolism of 
dual P-gp/CYP3A substrates was assessed in intestinal tissue from mice genetically 
deficient in P-gp and compared to that in normal mouse intestine.  Combination of 
these two models enabled better assessment of the results from each system.  
Using the rates of drug metabolism as a measure of the effect of P-gp, these studies 
were able to show that P-gp efflux could reduce the rate of metabolism of the dual 
substrate loperamide in both models and for terfenadine in the mouse model.   
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In order to help predict the effect of the transport/metabolism interaction at 
expected in vivo concentrations, a wide range of dosing concentrations was used for 
these studies.  This strategy revealed that the P-gp/CYP3A interaction is limited to a 
concentration range near the Km of metabolism for both substrates used.  
Combination of these results with pharmacokinetic modeling facilitated prediction of 
the effect of P-gp on intestinal metabolism of these substrates at physiologically 
relevant drug concentrations.  Further studies are planned to examine this 
interaction for dual P-gp/CYP3A substrates with different properties that are 
expected to influence the P-gp/CYP3A interplay. 
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Figure 4.1. Comparison of metabolite formation 
(A), parent in receiver (B), and extraction ratio 
of loperamide (20 µM dose) (C) in Caco-2 cell 
monolayers.   
n=3; error bars = SD. Stars indicate statistical 
significance (students’ t-test; p<0.05). 
C 
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Figure 4.2.  Proposed mechanism of P-gp activity: P-gp prevents drug from 
entering the cell by interacting with substrates within the apical membrane, 
while CYP3A acts inside the cell in the endoplasmic reticulum. 
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Figure 4.3. Calcein AM assay for P-gp activity.  Normal cell lacks P-gp 
efflux; MDR cell expresses P-gp.  Calcein AM is a P-gp substrate, while  
the esterase product calcein is not, so P-gp expressing cells accumulate  
less calcein, which is detected by fluorescence. (www.invitrogen.com) 
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A. ABSTRACT 
 
Purpose 
Both apical and basolateral efflux of fexofenadine appears to be mediated by 
MRPs.  The purpose of this study is to elucidate the role of MRPs, expressed in the 
apical and basolateral membranes, in the absorptive transport of fexofenadine 
across Caco-2 cells. 
 
Methods 
For the cellular efflux studies, Caco-2 cell monolayers were first incubated with 
fexofenadine on both apical and basolateral sides for 1 hour in the absence and 
presence of GW918 (P-gp inhibitor) and/or MK-571 (MRP inhibitor). The cells were 
then washed and transferred to fresh medium to measure the efflux of fexofenadine 
over a 2-minute period into both sides in the absence and presence of inhibitors.  
For the transport study, Caco-2 cell monolayers were first incubated with transport 
buffer with or without inhibitors for 30 minutes; the absorptive and secretory 
transport was performed by adding fexofenadine into the donor reservoir and 
measuring the transported compound  in the receiver compartment. Terfenadine, the 
parent drug of fexofenadine, was dosed to Caco-2 cells which expressed functional 
CYP3A and the distribution of fexofenadine, formed inside the cells, to basolateral 
and apical sides was measured over 120 minutes in the presence and absence of 
GW918. 
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Results 
GW918 and MK-571 stimulated the accumulation of fexofenadine into Caco-2 
cells by 4 and 2-fold, respectively, when cells were exposed to fexofenadine from 
both apical and basolateral sides.  Fexofenadine accumulated in cells was 
preferentially transported out of the cells across the apical membrane.  When P-gp 
was inhibited, fexofenadine was effluxed primarily to the basolateral side.  MK-571 
inhibited the efflux of cellular fexofenadine across the apical and basolateral 
membranes by 40% and 50%, respectively.  MK-571 decreased the absorptive 
transport rate slightly; however, it increased the secretory transport rate by 30%. 
When fexofenadine was formed from terfenadine metabolism in CYP3A-expressing 
cells, it was primarily effluxed to the apical side; however, in the presence of 
GW918, most of the compound was transported to the basolateral side. 
 
Conclusions 
The present study suggests that the MRP(s) and P-gp in the apical membrane 
may attenuate the absorptive transport by efflux of fexofenadine into GI lumen, 
whereas the MRP(s) in the basolateral membrane facilitates the absorption by 
causing egress of fexofenadine from the enterocytes to the serosal side.   
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B. INTRODUCTION 
 
Both apical (AP) and basolateral (BL) efflux of fexofenadine appear to be 
mediated by multidrug resistant associated proteins (MRPs) in addition to the apical 
efflux mediated by P-glycoprotein (P-gp).  The purpose of this study was to elucidate 
the roles of these transporters in the transport of fexofenadine in Caco-2 cells. 
 
Intestinal absorptive transport involves entry into the enterocytes across the 
apical membrane from the GI lumen and exit from the cells across the basolateral 
membrane. Depending on their relative efficiency and capacity, an uptake 
transporter in the apical membrane or an efflux transporter in the BL membrane can 
become rate-limiting for transepithelial movement (Cheeseman, 1992). However, 
compared with the clear roles of apical transporters in the transcellular transport 
process, it is still unclear whether BL transporters play an important role in intestinal 
transport. 
 
Fexofenadine has been used as a suitable probe to investigate carrier mediated 
transport processes due to its low passive permeability and relatively low extent of 
metabolism (Petri et al., 2004). In the apical membrane of enterocytes, organic anion 
transporting polypeptide 1A2 (OATP1A2) mediates the uptake process of 
fexofenadine into enterocytes (Cvetkovic et al., 1999). Fexofenadine is also a good 
substrate of the apical efflux transporter P-gp (Cvetkovic et al., 1999); several clinical 
reports have suggested that intestinal P-gp was the main site for drug-drug 
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interaction (Yasui-Furukori et al., 2005; Shimizu et al., 2006). However, it is still unclear 
whether the BL egress of fexofenadine is a transporter mediated process, and 
whether MRPs are involved in the intestinal transport of fexofenadine (Figure I.1). 
 
In this study, we first studied the distribution of fexofenadine which was formed 
by terfenadine metabolism in CYP3A-expressing Caco-2 cells with or without 
inhibition of P-gp. Then, the efflux of fexofenadine after preloading was examined to 
evaluate the possible role of MRPs. Finally, absorptive and secretory transport were 
studied to assess the significance of these transporters in the transport of 
fexofenadine in Caco-2 cells.  
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C. METHODS 
 
C.1. Cell Culture 
Caco-2 cells were cultured at 37°C in MEM, supplemented with 10% FBS, 1% 
NEAA, 1% antibiotic-antimycotic solution in an atmosphere of 5% CO2. Caco-2 cells 
were seeded at a density of 60,000 cells/cm2 on TranswellTM filters. Medium was 
changed the day after seeding, and every other day thereafter. The cells were 
cultured for 21-25 days before use. 
 
To induce CYP3A activity, the Caco-2 cells were seeded onto laminin-coated 
culture inserts at a density of 500,000 cell/cm2. After reaching confluence, the cell 
cultures were maintained in DMEM including 1α,25-(OH)2-D3 (0.5 µM) for 14 days. 
 
C.2. Accumulation and Efflux studies 
Caco-2 cell monolayers were incubated for 1 hour with 100 µM fexofenadine in 
both AP and BL sides in the absence or presence of inhibitors. After washing both 
sides 3 times with cold transport buffer (HBSS containing HEPES and glucose), 
efflux was determined over 2 minutes in the absence or presence of inhibitors. Then 
monolayers were dissolved in 300 µl 1% Triton X-100 for 4 hr with shaking and the 
solution was extracted with 1 ml ethyl acetate. The organic phase was evaporated to 
dryness under nitrogen gas, and the residue was reconstituted with 200 µl 25% 
methanol. The samples were analyzed by LC-MS/MS with cetirizine as internal 
standard. 
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C.3. Transport Study 
Caco-2 cell monolayers were incubated for 30 min with transport buffer. 
Transport studies were initiated by replacing the donor chamber with 10 µM 
fexofenadine in the absence or presence of inhibitors. The receptor chamber was 
sampled at selected times and analytes were quantified by LC-MS/MS. 
 
C.4. Distribution of Fexofenadine Formed from Terfenadine 
Terfenadine, the parent drug of fexofenadine, was dosed at 20 µM to Caco-2 
cells which expressed functional CYP3A; the distribution of fexofenadine, formed 
inside the cells, to BL and AP sides was measured over 120 minutes in the presence 
and absence of 1 µM GW918. 
 
C.5. Data Analysis 
Data were expressed as mean ± S.D. from three measurements. Statistical 
significance was evaluated using unpaired t tests or ANOVA followed by Tukey’s 
test for multiple comparisons. The apparent permeability coefficient was calculated 
according to the following equation: dt
dQ
CA
P
o
app ×
×
=
1
 
where dQ/dt is the flux across the cell monolayers with the surface area of A. C0 is 
the initial dose concentration. 
D. RESULTS AND DISCUSSION 
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When fexofenadine was formed from terfenadine metabolism in CYP3A-
expressing cells, it was primarily effluxed to the AP side; however, in the presence of 
GW918 (1 µM), most of the compound appeared in the BL side (Figure I.2). These 
results reveal the presence of an efflux transporter for fexofenadine in the BL 
membrane.  GW918 (1 µM) and MK-571 (25 µM) stimulated the accumulation of 
fexofenadine into Caco-2 cells by 4 and 2-fold, respectively, when cells were 
exposed from both sides (Figure I.3). These results suggest the involvement of 
MRP, in addition to P-gp, in fexofenadine efflux from Caco-2 cells. 
 
MK-571 (25 µM) inhibited the efflux of cellular fexofenadine across the AP and 
BL membranes by 40% (Figure I.4) and 50% (Figure I.5), respectively, indicating the 
involvement of MRPs in both AP and BL efflux of fexofenadine from Caco-2 cells.  
After preloading, fexofenadine was preferentially transported out of the cells across 
the AP membrane by 2-fold (Figure I.4). When P-gp was inhibited, efflux to the BL 
side was preferred by 1.5-fold (Figure I.5). 
 
GW918 nearly completely inhibited apical efflux, indicating the strong effect of P-
gp (Figure I.4).  Surprisingly, GW918 also inhibited basolateral efflux of fexofenadine 
(Figure I.5).  This may be indirectly caused by the high intracellular concentration 
attained after preloading with GW918.  MK-571 at 25 µM slightly decreased the 
absorptive transport (Figure I.6). When P-gp was inhibited, further treatment with 
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MK-571 decreased the transport rate by 25% (Figure I.6).  MK571 alone increased 
the secretory transport rate by  30 % (Figure I.7). 
 
E. CONCLUSIONS 
 
The present study suggests that fexofenadine appears to be a substrate for 
MRP(s) in AP membrane and MRP(s) in BL membrane of human intestine.  Based 
on known cellular distribution of MRPs in intestine, MRP2 and MRP3 may be the 
candidate transporters in AP and BL membrane, respectively. 
 
Although MRP2 may also be a player, P-gp appears to dominate apical efflux of 
fexofenadine.  MRP(s) in BL membrane limit secretory transport and could facilitate 
absorption by causing egress of fexofenadine from the enterocytes to the serosal 
side, but the one(s) in AP membrane may counteract the BL transporter by 
mediating AP egress.  Specific siRNA knockdown is desired to evaluate the relative 
contribution of individual MRPs. 
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Figure I.1.  Model for intestinal transport of fexofenadine 
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Figure I.2. Disposition of fexofenadine during absorptive 
transport of terfenadine across Caco-2 cells.  Mean of 3 ± 
SD.  A statistical difference was observed between 
appearance of fexofenadine in apical and basolateral 
chambers, under treated and untreated conditions 
(p<0.05, student’s t-test). 
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Figure I.3. Accumulation of fexofenadine after 
preloading in Caco-2 cells.  Mean of 3 ± SD. A 
statistical difference was observed between all 
treated and untreated conditions (p<0.05, 
student’s t-test). 
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Figure I.4. AP efflux of fexofenadine in Caco-2 cells.  
Mean of 3 ± SD. A statistical difference was observed 
between all treated and untreated conditions (p<0.05, 
student’s t-test). 
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Figure I.5.  BL efflux of fexofenadine in Caco-2 cells.  
Mean of 3 ± SD.  A statistical difference was observed 
between all treated and untreated conditions (p<0.05, 
student’s t-test). 
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Figure I.6. Absorptive transport of fexofenadine in  
Caco-2 cells.  Mean of 3 ± SD.  A statistical 
difference was observed between treated and 
untreated conditions for GW918 and dual treatments 
(p<0.05, student’s t-test). 
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Figure I.7. Secretory transport of fexofenadine in 
Caco-2 cells.  Mean of 3 ± SD.  A statistical 
difference was observed between treated and 
untreated conditions for GW918 and dual treatments 
(p<0.05, student’s t-test). 
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A. ABSTRACT 
Purpose 
P-glycoprotein (P-gp)-deficient mice are thirty times more sensitive to the peptidic 
opioid DPDPE than corresponding P-gp-competent mice.  The competent mice have 
a 10-fold higher brain EC50, which is the concentration required to produce 50% of 
the maximum antinociceptive response.  This discrepancy cannot be explained fully 
by the difference in brain penetration; this implies that P-gp has other functions in 
the brain besides efflux at the luminal membrane of the capillary endothelium. 
Methods 
A mathematical modeling approach was used to assess the mechanism of the 
difference in EC50.  A pharmacokinetic/pharmacodynamic model was proposed 
which attributes the difference in sensitivity to pharmacokinetic processes. 
Results 
The model identified is consistent with in vivo results; it includes a central and 
peripheral compartment, plus three brain compartments.  Brain EC50 was estimated 
at 0.166 µg/ml in the P-gp-competent mice, but was only 0.012 µg/ml in the P-gp-
deficient mice.  The model required inclusion of P-gp at sites other than endothelial 
cell membranes. 
Conclusions 
Concentration profile and antinociceptive effect data collected in DPDPE-treated 
P-gp-competent and -deficient mice can be characterized by a pharmacokinetic / 
pharmacodynamic model in which the role of P-gp in modulating receptor response 
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is critical.  An understanding of this link between pharmacokinetics and effect could 
significantly change the goals of CNS drug development. 
 
B. INTRODUCTION 
 
Studies have shown that many opioids are P-glycoprotein (P-gp) substrates.  
Chen et al. showed that P-gp-deficient mice required 30-fold lower doses of the 
peptidic opioid (D-Penicillamine2,5)enkephalin (DPDPE) than P-gp-competent mice 
to produce equivalent antinociception(Chen and Pollack, 1998). However, the P-gp-
deficient animals exhibited a brain/serum ratio of DPDPE which was only ~3-fold 
higher, indicating that P-gp may have additional barrier functions in the brain beyond 
efflux at the blood-brain barrier (BBB), consistent with reported extra-endothelial 
localization of P-gp in brain(Golden and Pardridge, 1999). This study was conducted to 
evaluate the linkage between P-gp-mediated transport and opioid 
pharmacodynamics. 
 
P-glycoprotein (ABCB1 or P-gp) is a 170 KD protein that resides in the cell 
membranes of many tissues.  It is encoded by the MDR1 gene in humans, while in 
mice the mdr1a and mdr1b gene products both play important roles.  P-gp acts as 
an efflux transporter that pumps xenobiotics out of cells, deriving energy from ATP 
hydrolysis. 
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The importance of P-gp in the central nervous system (CNS) is well established.  
The efflux transporter is expressed in the capillary endothelial cells of the blood-
brain barrier (BBB), where it restricts the entry of drugs via the transcellular route.  
The endothelial cells themselves considerably limit paracellular passage of 
molecules from the blood to the brain parenchyma due to the presence of tight 
junctions between cells. 
 
One relationship that has not been adequately explored is the effect of P-gp 
activity on pharmacodynamic response.  In particular, some data suggest that P-gp 
may be able to modulate the effect of substrates that are ligands for the opioid 
receptor(Chen and Pollack, 1998).   
 
Most pain relieving drugs that have been developed to target this family of 
receptors are mu-receptor type agonists, but recently there has been an increased 
interest in utilizing the delta-opioid receptor as a therapeutic drug target.  Some 
information suggests that delta-agonists have the potential to be at least as effective 
as mu-agonists at treating pain, but with a reduction in the side effects associated 
with mu-agonists, such as constipation, respiratory depression and the development 
of physical dependence.  
  
Cyclization, one strategy used to improve the stability and increase the residence 
time of such drugs, was employed in development of the delta-opioid receptor 
agonist (D-penicillamine2,5)-enkephalin (DPDPE)(Kramer et al., 1989) (Figure II.1). 
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The pentapeptide (molecular weight 646 Da) exhibits enhanced metabolic stability; 
however, it is subject to rapid biliary excretion(Chen and Pollack, 1997).  The passive 
permeability of DPDPE at the blood-brain barrier is quite low.  It has, however, been 
shown to enter the brain through a saturable mechanism(Dagenais C, 2001), and is 
subject to active efflux by  P-gp(Chen and Pollack, 1999). 
 
A previous in vivo study (Chen and Pollack, 1998) compared the disposition and 
effect of tritium-labeled DPDPE in “P-gp knockout” mice, which lack the gene for P-
gp expression (mdr1a(-/-)) with that in wild-type (P-gp competent) FVB mice 
(mdr1a(+/+)).  Although systemic pharmacokinetics were not altered by the mutation,  
the lack of P-gp at the BBB increased brain penetration of [3H]DPDPE 2–4 fold in the 
mdr1a(-/-) mice.  As expected, knockout mice exhibited a higher response to 
DPDPE; i.e. a much smaller dose was required for antinociception.  This was 
reflected in an approximately 30-fold lower ED50 value - the dose of drug required to 
elicit 50 % of the maximal response - in knockout mice.  However, this reduction in 
ED50 could not be attributed to enhanced permeation of the BBB alone.  
Measurement of the respective brain concentrations revealed a significant difference 
in sensitivity, even after normalization for brain concentrations (Figure II.2).  That is, 
the EC50 of brain tissue (concentration of drug in whole brain homogenate that will 
produce 50% of the maximal response) was approximately 10 times lower in the 
mdr1a(-/-) mice versus the mdr1a(+/+) mice.  This interesting finding remains 
unexplained. 
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Data generated by Pollack and colleagues provided evidence against the 
hypothesis of a change in intrinsic receptor response or number of receptors.  Since 
it was not possible to achieve identical brain concentrations in vivo in mdr1a(+/+) 
and mdr1a(-/-) mice due to the sensitivity of the knockout animals, an in vitro 
analysis was employed. The binding to membrane fractions of radiolabeled 
guanosine-5’-O-(3-[35S]thio)triphosphate (abbreviated [35S]GTPγS), an analog of 
GTP that is resistant to hydrolysis, was used as a measure of activation of G-protein 
coupled opioid receptors (methods described elsewhere(Selley et al., 1998)).  When 
this analysis was performed using membrane fractions from P-gp competent and 
deficient mouse brains, no significant difference in response (p>0.1) was found 
between the strains. 
 
Similarly, data were generated in the Pollack lab that ruled out differences 
between the P-gp competent and deficient mice in uptake or binding of [3H]DPDPE 
to brain slices in vitro (unpublished data, Matheny and Pollack).   
 
In the absence of a binding affinity or receptor activity alteration, the most likely 
mechanism for modulation of receptor response would be an alteration of drug 
pharmacokinetics.  If this were the case, the concentration at the receptor would 
produce the same response, but the drug would be restricted from the receptor 
biophase by the transporter.  This implies that P-gp could have additional roles in the 
CNS besides efflux at the level of the capillary endothelium. The possibility that P-
glycoprotein could modulate not only the pharmacokinetics, but also the 
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pharmacodynamics, of opioids requires additional investigation.  The aim of the 
investigations presented here is to examine in detail the pharmacodynamic link 
between P-gp transport and opioid receptor response, using a PK/PD modeling 
approach, and to explore possible causative mechanisms. 
 
C. MATERIALS AND METHODS 
 
All pharmacokinetic and pharmacodynamic modeling and simulation were 
performed using the program WinNonlin 4.1 (Pharsight Corp., Mountain View, CA).  
Although their data were not fit directly, information from the DPDPE study by Chen 
et al.(Chen and Pollack, 1998) was used in creating the models.  The goal of the 
modeling was to explain the data obtained and to draw conclusions which would 
allow predictions to be made.  Some of the parameters derived by the investigators, 
such as EC50, gamma and volume of the central compartment were used directly, 
while others were used as starting points for model construction.  The value of brain 
EC50 observed for the knockout mice was used to simulate the data, the goal being 
to find the model which would shift the brain EC50 to the level observed in competent 
mice.  Response was calculated using the Hill equation: 
γγ
γ
C EC50
C *Emax
  E
 
 
+
=
 
where E = effect, C = drug concentration and γ = sigmoidicity factor. 
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Since P-gp Vmax and Km values have not been reported for this compound, those 
obtained for a similar peptidic drug (DAMGO)(Oude Elferink and Zadina, 2001) were 
used as a starting point around which a range of values was examined.  An average 
mouse weight of 30 g, a total brain volume of 0.0038 ml, and a brain weight of 0.35 g 
were assumed.    Physiological volumes and scaling factors were obtained from the 
literature(Davies and Morris, 1993). 
 
Nine distinct pharmacokinetic/pharmacodynamic (PK/PD) model scaffolds were 
constructed; the ability of each to describe the disposition and action of DPDPE in 
both P-gp-competent and P-gp-deficient mice, based on previously reported 
data(Chen and Pollack, 1998), was evaluated. Standard selection criteria were 
employed, and a scaffold segregating the brain into 3 compartments (one containing 
the effect site) was identified for further experiments. All models assumed a 
stationary pharmacodynamic system over the time range evaluated (200 minutes).  
 
Factors used to compare the models included the relative levels of brain and 
blood concentrations and the shapes of the concentration-time curves as well as 
Akaike’s Information Criterion.  Most importantly, the effect of P-gp on the dose-
response curve (EC50) was examined (Figure II.3).  
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D. RESULTS AND DISCUSSION 
 
     A model was identified (Figure II.4) that describes the phenomenon observed by 
Chen et al.  The 10-fold increase in brain EC50 of P-gp competent versus P-gp 
deficient mice can be accounted for by the presence of P-gp at sites other than the 
endothelial cell luminal membranes.  The model includes a central compartment, 
plus a peripheral compartment to account for systemic disposition.  Characterization 
of brain pharmacokinetics called for separation of the brain into three compartments 
– endothelial cells (2), parenchyma (4) and cerebrospinal fluid (3).   
The differentials used in the model were as follows: 
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where C represents concentration, X represents mass, k values represent the 
first-order rate constants for compound movement between compartments, Vmax 
represents the maximum rate of efflux, and Km represents the concentration at which 
half of maximum efflux is achieved.  As can be seen in Figure II.5, the blood 
concentration profiles after a 10 mg/kg dose were predicted to coincide in the two 
 181 
strains of mice (P-gp competent versus deficient, respectively).  Effect, however, 
was markedly different in magnitude and duration.  The dose required to produce a 
50% response (ED50) was estimated to be 21 mg/kg for the wild-type, but only 0.9 
mg/kg for the knockout mouse.  As shown in C-D, brain concentrations were higher 
in the knockout mice at equivalent dosage levels.  Brain EC50 was estimated at 
0.166 µg/ml in the P-gp competent mice, but only 0.012 µg/ml in the P-gp deficient 
mice. 
 
 Figure II.6 shows the change in area under the effect curve (AUEC), 0 to 200 
minutes, calculated using the linear trapezoidal method, with varying Vmax to Km 
ratios (intrinsic efflux clearance) at a fixed dose.  It is clear that pharmacodynamic 
effect decreases rapidly with increased rates of efflux.  
 
 Sensitivity analyses were performed for the model by varying certain parameters 
and simulating the effect on system response.  The parameter k12 describes the 
penetration of drug through the endothelial cell layer; as this parameter changes, the 
expected receptor response shows large changes at early time points.  This 
underscores the importance of the tight junctions at the blood-brain barrier, which 
keep permeability quite low.  It may also be indicative of the active uptake of DPDPE 
across the blood-brain barrier by a saturable mechanism, which may be a member 
of the organic anion transporting polypeptide (OATP) family (Dagenais C, 2001).  This 
aspect of DPDPE disposition has not been included in the model for simplicity.  
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E. CONCLUSIONS 
 
     Parameter sensitivity analysis and comprehensive PK/PD simulations revealed 
that DPDPE pharmacodynamics were exquisitely sensitive to P-gp when the 
transporter was not localized only to the BBB.  These results support the hypothesis 
that P-gp presents tertiary barriers for substrate presentation to opioid receptors in 
brain. Potential synergistic barrier functions of efflux transporters at multiple sites in 
brain should be considered in assessing the influence of such transporters on CNS 
pharmacodynamics. 
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Figure II.1. Structure of DPDPE 
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Figure II.2. Brain concentration vs. effect profiles for P-gp deficient (open 
circles) and P-gp competent (closed circles) mice.  Chen and Pollack, 1998 
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Figure II.3.  Simulated brain concentration vs. effect profiles for nine 
PK/PD models. 
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Figure II.4. The model used to simulate PK/PD data. Note: C represents 
concentration, X represents mass, k values represent the first-order rate 
constants for compound movement between compartments, Vmax 
represents the maximum rate of efflux, and Km represents the 
concentration at which half of maximum efflux is achieved.    
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Figure II.5. Predicted blood and brain concentration-response profiles 
generated from the selected model. Panels A and C portray the data from the 
P-gp competent mice, and panels B and D show the data from the P-gp 
deficient mice. 
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Figure II.6. The effect of changes in intrinsic efflux rate (Vmax/Km) on 
pharmacodynamic response. 
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A. ABSTRACT 
 
Purpose 
The aims of this project were to develop methods of quantifying antineoplastic 
drugs in isolated nuclei in order to understand drug distribution mechanisms in drug 
resistant and drug sensitive cell lines. 
Methods 
A sucrose gradient method was developed for isolation of nuclei from disrupted 
cells.  Acetonitrile was used to extract the drug from the nuclei.  HPLC methods 
were developed for each compound.  In addition, fluorescence microscopy was used 
to visualize the distribution of compounds within intact drug sensitive and drug 
resistant cell lines. 
Results and Discussion 
Nuclear fractionation, extraction, and HPLC quantification methods were 
successfully developed for several compounds.  CEM-C1 (drug resistant) nuclei 
accrued slightly less drug than their untransformed counterparts (CEM).  Similarly, 
there was a striking reduction in the HL60R (drug resistant) cell nuclei compared to 
the corresponding drug sensitive cells (HL60S) due to development of drug 
resistance mechanisms.  Camptothecin and daunorubicin appeared to accumulate in 
punctate cellular compartments in the drug-resistant cell line when examined by 
fluorescence microscopy. 
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Conclusions 
Drug resistance mechanisms in HL60R and CEM-C1 cell lines involve 
redistribution of compound within the cell away from the nucleus (site of action). 
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B. INTRODUCTION 
 
Understanding the distribution of drugs within cells is an important goal in drug 
delivery.  Drug targets are often located within the nucleus (e.g., for gene delivery) or 
other organelles.  Elucidating the factors which determine the intracellular 
localization of a compound would allow better design of drugs that target specific 
compartments.  These factors include binding specificity as well as physicochemical 
parameters such as pKa and lipid partitioning.  For example, weakly basic drugs 
have been shown to accumulate in lysosomes and other acidic organelles due to the 
ion trapping phenomenon (Hurwitz et al., 1997) (de Duve et al., 1974) (Chou et al., 
2001).  In addition, hydrophobic cationic compounds accumulate in the mitochondria 
due to the net negative membrane potential of these organelles (Hatefi, 1985). 
 
The properties of specific cell types can also determine intracellular distribution.  
For example, the lipid composition of the membranes as well as the expression of 
membrane-bound proteins may differ between cell types.  The changes associated 
with development of multidrug resistance in cells are particularly interesting.  
Multidrug resistance (MDR) occurs when cells are chronically exposed to certain 
drugs, including many anticancer agents. While it is known that drug efflux 
transporters are overexpressed in multidrug resistant cells, many other changes that 
are less understood are associated with this transformation (Larsen et al., 2000).  
These adaptive changes may influence the intracellular distribution of compounds 
such that the drugs can no longer reach their targets (e.g., nucleus). 
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In order to study the intracellular distribution of therapeutic agents, as well as 
changes in distribution associated with development of multidrug resistance, 
methods must be available to separate the different components of the cell.  Most of 
the studies done in this area involve visualization of drug distribution by fluorescence 
microscopy.  However, isolation of individual organelle types would allow accurate 
quantification of drug levels in these compartments.  In this study, a cell fractionation 
approach (Duvvuri et al., 2004), coupled with HPLC with fluorescence detection, has 
been used in an effort to better understand intracellular drug distribution. 
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C. MATERIALS AND METHODS 
 
The HPLC system consisted of a Waters 600S Controller, Waters 616 Pump, 
Waters 474 Scanning Fluorescence Detector, Waters 717plus Autosampler and 
Shimadzu C-R3A Chromatopac Integrator.  Tetraethylammonium acetate was 
purchased from Pfaltz and Bauer.  Glacial acetic acid, acetonitrile and potassium 
hydroxide were purchased from J.T. Baker.  Sucrose, sodium phosphate and 
potassium phosphate were purchased from Mallinckrodt.  Potassium chloride was 
purchased from EM Science.  Sodium chloride, camptothecin, DMSO, TEA, PBS, 
daunorubicin and SR-101 were purchased from Sigma Aldrich.   Doxorubicin was 
purchased from Alexis.  Formic acid and ammonium formate were purchased from 
Fisher Scientific.  RPM1 medium with L-glutamine was purchased from Gibco.  
C.1. Cell Culture 
CEM, CEM-C1, HL60R and HL60S cells were routinely grown in suspension in 
RPM1 medium with L-glutamine and split every 4-5 days.  Cells were incubated at 
37oC at 95% humidity and 5% CO2. 
C.2. Cell Incubations 
HL-60S (drug sensitive) and HL-60R (drug resistant) as well as CEM (drug 
sensitive) and CEM-C1 (drug resistant) cell lines were used at a concentration of 8.7 
X 107 cells per prep.  Cells were incubated with each drug for 2 hours @ 37oC. 
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C.3. Nuclear Fractionation 
The separation of intact nuclei from cells was carried out using a slightly modified 
version of the procedure by Duvvuri, et al. (Duvvuri et al., 2004)  Briefly, 8.0 x 107 
cells were incubated in 0.5 µM of daunorubicin for 2 hours at 37oC, pelleted, and 
washed twice with ice-cold PBS, pH 7.4.  The cells were resuspended in 10 ml of 
0.25 M sucrose in TKMC buffer (50 mM Tris, 25 mM KCl, 5 mM MgCl2, pH 7.0), and 
homogenized in a Dounce homogenizer with a tight-fitting B pestle.  Ten ml of 2.3 M 
sucrose in TKMC buffer containing 0.75% Triton-X 100 were added and this solution 
was layered on top of 2.3 M sucrose in TKMC buffer and centrifuged at 15,000 rpm 
in a Beckman SW28 swinging bucket rotor for 70 minutes at 4oC. 
 
C.4. Extraction of Drug 
Acetonitrile (750 µL) was added to the pelleted nuclei.  The samples were then 
sonicated for 15 minutes and centrifuged for 10 minutes at 13,000 rpm.  Next, 500 
µL of supernatant were evaporated to dryness and reconstituted in 50 µL of mobile 
phase for analysis.  The residues from the samples were reconstituted with MeOH 
and dilute HCl, then treated as above, to determine whether any drug was still bound 
to the cell DNA after extraction.   
 
C.5.  Extraction Efficiency 
The following concentrations were extracted: 50 nM, 100 nM, 150 nM and 200 
nM.  Each preparation contained 126 X 106 HL-60 S cells.  The separation and 
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extraction were carried out as previously described, except a single 1000 µl portion 
of ACN was used instead of two 500 µl portions of ACN: MeOH, for the extraction. 
 
C.6. Fluorescence Microscopy 
Cells were incubated with drug (camptothecin = 50 µM; daunorubicin = 1 µM) for 
1 hour at 37oC, then centrifuged 5 min @ 1000 rpm.  Media was removed and cells 
were washed with 1 ml ice-cold PBS pH 7.4 and centrifuged 5 min @ 1000 rpm. 
PBS was removed and cells were washed with 1 ml ice-cold PBS (pH 7.4) and 
centrifuged 5 min @ 1000 rpm. PBS was removed and 10 µl cell mounting solution 
was added.  The result was transferred to a microscope slide w/coverslip and 
sealed. 
 
C.7. Quantitation of Camptothecin by HPLC 
A HPLC method was developed to quantify Sulforhodamine-101. The method 
utilized a flow rate of 0.7 ml/min, an injection volume of 20 µl and a run time of 10 
minutes.  Fluorescence detection was employed with an excitation wavelength of 
360 nm and an emission wavelength of 440 nm.  Optimal wavelengths were 
determined by scanning the 100 nM standard.  Mobile phase consisted of 675 ml 
TEAA buffer buffer 1.5% (pH adjusted to 5.5 with glacial acetic acid) and 225 ml 
acetonitrile.  The column was a Waters Symmetry C18 (3.0 x 100 mm). 
 
C.8. Quantitation of Daunorubicin and Doxorubicin by HPLC 
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A HPLC method was developed to quantify both daunorubicin and doxorubicin. 
The method utilized a flow rate of 0.3 ml/min, an injection volume of 20 µl and a run 
time of 10 minutes.  Fluorescence detection was employed with an excitation 
wavelength of 470 nm and an emission wavelength of 550 nm.  Optimal 
wavelengths were determined by scanning the 100 nM standard.  The mobile phase 
for doxorubicin consisted of 770 ml ammonium formate buffer (pH adjusted to 3.0 
with formic acid) and 230 ml acetonitrile.  For daunorubicin, 900 ml of the 
doxorubicin mobile phase was combined with 100 ml acetonitrile.  The column was 
an X-terra MS C18 (3.5µm, 2.1 x 150 mm). 
 
C.9. Quantitation of Sulforhodamine-101 by HPLC 
A HPLC method was developed to quantify Sulforhodamine-101. The method 
utilized a flow rate of 0.5 ml/min, an injection volume of 10 µl and a run time of 8 
minutes.  Fluorescence detection was employed with an excitation wavelength of 
320 nm and an emission wavelength of 580 nm.  Optimal wavelengths were 
determined by scanning the 100 nM standard.  Mobile phase consisted of 1190 ml 
ammonium formate buffer (pH adjusted to 3.0 with formic acid) and 510 ml 
acetonitrile.  The column was an X-terra MS C18 (3.5µm, 2.1 x 150 mm). 
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D. RESULTS 
 
HPLC methods were successfully developed for all four compounds 
(camptothecin, doxorubicin, daunorubicin and SR-101).  As shown in Figure III.1, the 
camptothecin (CPT) HPLC method worked well after several adjustments to the 
method, producing acceptable peak shape for CPT as well as its lactone form.  The 
standard curve was linear up to 100 nM.  Figure III.2 shows the peak shape as well 
as the standard curve for doxorubicin (DOX).  For daunorubicin (DNR), a very similar 
method was used, which also produced good linearity.  Figure III.3 shows the 
standard curve for SR-101, which also looked quite linear.  For all of the methods 
developed, r2 values for the standard curves were greater than or equal to 0.999. 
 
A cell fractionation approach, using differential centrifugation, was used to 
separate nuclei from organelles after drug treatment.  Extraction efficiency was 
determined for SR-101 and daunorubicin by spiking cells with compound then 
carrying out the fractionation.  Acceptable recovery values (~50%) were obtained for 
both compounds (Tables III.1 and III.2). 
 
Next, cells were incubated with either doxorubicin (for CEM and CEM-C1 cell 
lines) or daunorubicin (for HL60S and HL60R cell lines).  The cells were washed and 
fractionated to isolate the nuclei.  Figure III.4 compares doxorubicin accumulation in 
nuclei of CEM (drug-sensitive) and CEM-C1 (drug resistant) cells.  CEM-C1 nuclei 
accrued slightly less drug than their untransformed counterparts.  Similarly, Figure 
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III.5 compares daunorubicin accumulation in nuclei of HL60S (drug-sensitive) and 
HL60R (drug-resistant) cells.  There was a very significant reduction in the HL60R 
cell line due to development of drug resistance mechanisms. 
 
Finally, the intracellular distribution of antineoplastic drugs was examined for the 
CEM and CEM-C1 cell lines by fluorescence microscopy.  Figure III.6 shows that 
camptothecin is more concentrated in intracellular organelles outside of the nucleus 
in the drug resistant cell line.  In order to better visualize this difference we 
attempted to increase the camptothecin treatment concentration, but this resulted in 
precipitation of the compound and unclear visualization of distribution (Figure III.7).   
 
Similar to camptothecin, daunorubicin accumulated in punctate cellular 
compartments in the drug-resistant cell line (Figure III.8).   
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E. DISCUSSION 
 
The HPLC methods worked well for easy quantification of camptothecin, 
doxorubicin, daunorubicin, and sulforhodamine-101 (Figures III.1-3).  The extraction 
method produced acceptable recovery values (Table III.1). 
 
Drug-resistant cells (CEM-C1) accumulated slightly less doxorubicin in their 
nuclei than drug-sensitive cells (CEM) (Figure III.4).  HL60 drug-sensitive cell nuclei 
accumulated significantly more daunorubicin than the corresponding drug-resistant 
cell nuclei (p=0.01) (student’s t-test) (Figure III.5).  The HL60R cell line appears to 
more effectively partition drug away from the nucleus.  This method does not, 
however, distinguish whether drug was excluded from the cell or sequestered in a 
secondary compartment. 
 
For the fluorescence microscopy, the camptothecin signal was at first weak, 
which made visualization difficult, although some differences can be seen in the 
nuclear accumulation of the sensitive (CEM) and resistant (CEM-C1) cells (Figure 
III.6).  The experiment was repeated with a higher concentration of camptothecin 
(Figure III.7), but this resulted in precipitation of the compound and unclear 
visualization.  Daunorubicin, however, clearly distributed to punctuate compartments 
in the drug resistant cell line.   
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F. CONCLUSIONS 
 
HPLC methods were developed for camptothecin, doxorubicin and daunorubicin, 
and SR-101.  A method of nuclear isolation and extraction of drug was validated.  
Daunorubicin exhibited a large difference in the amount accumulated in the nucleus  
between CEM and drug-resistant CEM-C1 cells, with the resistant cells 
accumulating significantly more compound.  Doxorubicin showed the same trend in 
HL60R cells compared with HL60S cells, but the difference was minimal.  
Camptothecin and daunorubicin showed different distribution patterns in drug-
resistant and drug-sensitive cells. The mechanisms of redistribution of drugs away 
from the nuclear target are likely to be compound- and cell line-specific.   
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Figure III.1. Standard curve and representative 
chromatogram for camptothecin (CPT) 
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Figure III.3. Standard curve for SR-101. 
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CEM Cells (drug-sensitive) + 10 µM CPT              CEM-C1 Cells (drug-resistant) + 10 µM CPT 
 
Figure III.6.  Visualization of camptothecin distribution in CEM and CEM-
C1 cells by fluorescent microscopy. 
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PRECIPITATED CAMPTOTHECIN 
 
CEM (drug-sensitive) + 50 µM CPT                   CEM-C1 (drug-resistant) + 50 µM CPT 
 
Figure III.7. Upper panel: precipitation of camptothecin.  Lower panels: 
Visualization of camptothecin distribution in CEM and CEM-C1 cells by 
fluorescent microscopy. 
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CEM Cells (drug-sensitive) + 1 µM  DNR                     CEM-C1 Cells (drug-resistant)+ 1 
µM DNR 
Figure III.8. Visualization of daunorubicin distribution in CEM and CEM-C1 
cells by fluorescent microscopy. 
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Table III.1. Extraction efficiency for SR-
101 in HL60S cells. 
 
Theoretical Conc. Recovery
50 nM 41.7%
100 nM 50.7%
150 nM 61.4%
200 nM 54.3%
Average 52.0%
SD 8.2%
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Table III.2. Extraction efficiency for daunorubicin. 
 
Cell Type Theoretical Conc. Recovery
HL60S 200 nM 57.1%
HL60S 400 nM 48.7%
HL60R 200 nM 52.1%
HL60R 400 nM 53.2%
Average 52.8%
SD 3.5%
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APPENDIX IV: WHY IS ABSORPTIVE 
METABOLISM HIGHER THAN 
SECRETORY METABOLISM IN 
INTESTINE?          
Beverly M. Knight and Dhiren R. Thakker 
AAPS 2007                          
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A. ABSTRACT 
 
Purpose 
Caco-2 cells are often used to study the interplay between drug transporters 
and metabolic enzymes in the intestine.  It has been reported that B-to-A 
(basolateral to apical) metabolism is often slower than A-to-B metabolism (Gan et 
al., 1996) (Paine et al., 2002a) (Raeissi et al., 1999).  Therefore, the cause of this 
effect was investigated.   
 
Methods 
Side-by-side diffusion chambers were used to study the transport and 
metabolism of terfenadine and loperamide in intestinal tissue from P-gp-deficient 
and P-gp-competent mice during its absorptive transport.  Three jejunal 
segments (0.3 cm2) were excised from each mouse and immediately mounted 
between two chambers containing Krebs-Ringer Bicarbonate buffer; viability was 
maintained by bubbling the solution with oxygen:carbon dioxide (5:95).  After a 
30-minute equilibration, substrate was dosed into the donor chamber.  Samples 
were collected over 120 minutes.  Caco-2 cell monolayers were cultured in 
Transwell® plates and induced to express CYP3A according to published 
methods (Schmeidlen-Ren et al., 1999).  The transport across Caco-2 cell 
monolayers of terfenadine and loperamide was characterized in the A-to-B and 
B-to-A directions and also in the presence and absence of the P-gp inhibitor 
GW918.  During transport of loperamide or terfenadine, CYP3A-specific 
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metabolites formed over time in all three compartments were quantified using 
LC-MS/MS. 
 
Results 
In Caco-2 and mouse intestine, the rate of metabolism in the A-to-B direction 
was higher than that in the B-to-A direction for both terfenadine and loperamide.  
When Caco-2 cells were treated with P-gp inhibitor GW918, the metabolism of 
loperamide was increased in both directions, but the A-to-B metabolism 
remained significantly higher (~6 fold) compared to B-to-A metabolism.  
Accordingly, metabolism of terfenadine by P-gp-deficient mouse intestine 
showed a polarity in B-to-A vs. A-to-B metabolism: the rate of A-to-B metabolism 
was about 2-fold higher than B-to-A metabolism. 
 
Conclusions 
Some authors have postulated that the enhancement of metabolism observed 
in the A-to-B direction is due to drug efflux by P-glycoprotein (P-gp).  However, 
since this inequality was not abolished by chemical P-gp inhibition or by genetic 
P-gp knockout, P-gp is not likely to be responsible.  More study is needed to 
elucidate the mechanisms behind this phenomenon. 
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B. INTRODUCTION 
Oral delivery is the most commonly used method of administering drugs.  It is 
therefore important to understand all of the mechanisms and barriers involved in 
the oral absorption of drugs.  Drug metabolizing enzymes and efflux transporters 
constitute two important barriers to drug absorption from intestine.  Drug 
metabolizing enzymes, such as the CYP (CYP) enzymes, have been extensively 
studied in the liver, but their role in intestine is not as well understood.  The most 
important of these enzymes is CYP3A, since it has the highest expression and 
widest substrate specificity.  There are many efflux transporters expressed in 
intestine, including MRPs (multidrug resistance associated proteins) and BCRP 
(breast cancer resistance protein) transporters, but the most studied transporter 
is P-gp.  P-gp functions to pump drug out of enterocytes and also has wide 
substrate specificity. 
 
The way in which these systems interact has been investigated.  There is 
thought to be functional interplay between CYP3A and P-gp in particular, given 
their overlapping substrate specificities, colocalization at the apical membrane of 
enterocytes, and similarity of protective function.  The first group to pioneer these 
studies used the Caco-2 cell line, a model of human intestinal epithelium.  They 
noted that metabolism of cyclosporine A was more extensive when compound 
was dosed on the apical (A) side of the cells than when dosed on the basolateral 
(B) side.  In other words, more metabolites were produced during absorptive (A-
to-B) permeation of the compound than during secretory (B-to-A) permeation.  
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The authors hypothesized that the metabolism was enhanced in the absorptive 
direction due to P-gp efflux at the apical membrane (Gan et al., 1996).  Since then, 
other authors have noted the same phenomenon for other substrates (Raeissi et 
al., 1999; Paine et al., 2002a). 
 
This work aimed to examine the underlying cause of these observed results 
more closely using two dual CYP3A/P-gp substrates, terfenadine and 
loperamide.  Mechanistic studies were carried out to determine whether P-gp 
efflux increase the extent of intestinal metabolism in the absorptive direction. 
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C. MATERIALS AND METHODS 
 
C.1. Chemicals and Reagents 
Terfenadine, loperamide, sodium selenite, zinc sulfate, all-trans retinoic acid, 
sodium hydroxide, Kreb’s Bicarbonate Ringer and gentamicin were purchased 
from Sigma Aldrich (St. Louis, MO, USA).  Metabolites of terfenadine 
(azacyclonol and fexofenadine) were generously provided by Dr. Mary Paine.   
Metabolites of loperamide (monodemethyl- and didemethyl-loperamide) were 
generously provided by Janssen (Beerse, Belgium).  GW918 was provided by 
GlaxoSmithKline.  Methanol, formic acid, ethyl acetate and vitamin E were 
purchased from Fisher Scientific (Pittsburgh, PA, USA).  Ketamine was 
purchased from Veterinary Medical Supply (Zebulon, NC, USA), and xylazine 
from Webster Veterinary (Sterling, MA, USA).  Eagle’s minimum essential 
medium with Earle’s salts and L-glutamate (MEM), Dulbecco’s Modified Eagle’s 
Medium with L-glutamine but without sodium pyruvate (DMEM), nonessential 
amino acids (NEAA, 100X), 0.05% trypsin-0.53 mM EDTA solution, N-
Hydroxyethylpiperazine-N’-2-ethanesulfonate (HEPES, 1 M) and penicillin-
streptomycin-amphotericin B solution (100X) were obtained from Gibco 
Laboratories (Grand Island, NY, USA).  Hank’s balanced salt solution (HBSS) 
was obtained from Mediatech, Inc. (Herndon, VA, USA).  1α, 25-dihydroxyvitamin 
D3 was obtained from Biomol (Plymouth Meeting, PA, USA).  Mouse laminin was 
purchased from BD Biosciences (San Jose, CA, USA).   
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C.2. Animals 
Mice (CF-1 wild type and P-gp mutant) were purchased from Charles River 
Laboratories (Wilmington, MA) and housed according to AAALAC requirements 
and protocols accepted by the University of North Carolina Institutional Animal 
Care and Use Committee.  The animal housing facility is under the supervision of 
the University’s Campus Veterinarian, and is in compliance with public laws 89-
544 and 91-579.  A full-time technician in the Department of Laboratory Animal 
Medicine is responsible for animal husbandry in this facility.  All personnel 
handling animals must first be certified by the university Institutional Animal Care 
and Use Committee.  Mouse liver and intestinal microsomes were purchased 
from Xenotech.  Human intestinal microsomes were generously provided by Dr. 
Mary Paine. 
 
C.3. Materials 
Corning plates (12-well) with Transwell™ inserts were purchased from Fisher 
Scientific (Pittsburgh, PA, USA); 6-well-plates and inserts were purchased from 
BD Biosciences (San Jose, CA, USA).  The side-by-side diffusion chamber 
system (Physiologic Instruments, San Diego, CA, USA) used for the animal 
studies was loaned by GlaxoSmithKline. 
 
C.4. Caco-2 Cell Culture 
The Caco-2 cell line, clone P27.7, was obtained from Mary Paine, Ph.D. and 
Paul Watkins, MD (Schools of Pharmacy and Medicine, The University of North 
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Carolina at Chapel Hill, Chapel Hill, NC, USA).  Caco-2 cell monolayers were 
cultured according to the methods of Lee and Thakker (Lee and Thakker, 1999).  
Except where noted, cell culture medium consisted of 500 ml Minimum Essential 
Medium (MEM), 50 ml Fetal Bovine Serum (FBS), 5 ml 100X Non-Essential 
Amino Acids (NEAA), and 5 ml 100X Antibiotic/Antimycotic (final concentrations: 
100 U/ml penicillin, 100 µg/ml streptomycin, and 0.25 µg/ml amphotericin B).  
Cells were grown in 75 cm2 tissue culture (T75) flasks at 37oC, in an atmosphere 
of 5% CO2 and 90% relative humidity, and subcultured at a 1:10 ratio, using 
0.05% trypsin/0.02% EDTA solution, upon reaching 90% confluency.   
 
C.5. Transwell® System 
For metabolic experiments, 6-well plates containing Biocoat cell culture 
inserts (4.2 cm2, 1 µM pore size) were coated with murine laminin (5 µg/cm2) and 
then were seeded with Caco-2 cell clone P27.7 (passages 29-42) (Schmeidlen-
Ren et al., (Schmiedlin-Ren et al., 1997)) at a density of 5 X 105 cells/cm2.  
Cultures were grown using growth medium (DMEM containing 20% heat-
inactivated FBS, 0.1 mM NEAA, 50 µg/ml gentamicin, and 45 nM vitamin E) until 
confluence, as assessed by transepithelial electrical resistance values 250 · 
cm2.  After that, the cells were treated for 14 days with differentiation medium 
(DMEM containing 5% heat-inactivated FBS, 0.1 mM NEAA, 50 µg/ml 
gentamicin, 45 nM vitamin E, 0.1 µM sodium selenite, and 3 µM zinc sulfate) as 
described by Schmeidlen-Ren et al. (Schmiedlin-Ren et al., 1997) and 
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supplemented with 0.5 µM 1 ,25-(OH)2-D3 and 0.2 µM all-trans-retinoic acid 
(Mouly et al., 2004) to induce CYP3A expression.  
 
C.6. Metabolic Studies 
To induce CYP3A expression, Caco-2 cell monolayers were grown on 
laminin-coated inserts in cell culture dishes, and treated with 0.5 µM 1 ,25-(OH)2-
D3 for 2 weeks postconfluence, as verified by TEER ≥ 250 Ω·cm2 (Schmiedlin-
Ren et al., 1997; Mouly et al., 2004).   After 90 min (loperamide) or 120 minutes 
(terfenadine), samples were collected from the donor and receiver 
compartments.  Cell monolayers were washed and harvested by scraping into 
500 µl of homogenization buffer (100 mM potassium phosphate, 0.25 M sucrose, 
and 1 mM EDTA, pH 7.4).  CYP3A-specific metabolites were identified for each 
substrate, and metabolite formation over time was characterized by quantification 
of parent remaining and metabolite formed in all three compartments (donor, 
cellular and receiver). Parent drug and metabolites were extracted from the 
lysates samples using a validated extraction procedure.  Briefly, samples were 
vortexed with 1 ml ethyl acetate, then centrifuged and the supernatant removed.  
The samples were then alkalinized with 50 µl 1 N sodium hydroxide and 
extracted with an additional 1 ml ethyl acetate.  The supernatants were 
combined, evaporated, and reconstituted in mobile phase. 
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C.7. Diffusion Chamber Studies 
 
Male CF-1 mice were anesthetized with an IP injection of ketamine (140 
mg/kg) and xylazine (15 mg/kg).  Just before sacrifice, the intestines were 
removed and immediately flushed with 10 ml ice-cold Krebs Bicarbonate Ringer 
(KBR).  Three portions of jejunum (~1 inch long) were retained for the analysis.  
Each section was cut longitudinally and then mounted between the two halves of 
a diffusion chamber insert and held in place by eight small pins.  The inserts 
were placed in ice-cold KBR until mounted between the chambers.  The entire 
procedure was carried out as quickly as possible, on ice. 
 
Inserts were mounted between two side-by-side diffusion chambers.  KBR (3 
ml) was added to each chamber and bubbled with oxygen/carbon dioxide gas to 
maintain viability.  After an equilibration period of 30 minutes, the TEER was 
measured, the buffer in the receiver side was replaced with fresh warmed KBR, 
and the buffer in the donor side was replaced with warmed dosing solution.  
Samples were removed from the chambers at the appropriate timepoints and 
replaced with fresh KBR.  At the end of the experiment, the tissues were 
removed and homogenized in 200 µL of KBR, then extracted with ethyl acetate 
as described for cell monolayers above. 
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C.8. Analysis of Terfenadine and Loperamide and Their Metabolites 
Terfenadine and its two metabolites, fexofenadine and azacyclonol, and 
loperamide and its two metabolites, monodemethyl-loperamide and didemethyl-
loperamide, were quantified using LC-MS/MS (LC10-ADVP quaternary pumps 
(Shimadzu, Kyoto, Japan), CTC-PAL autosampler (LEAP Technologies, 
Carrboro, NC, Sciex API-4000 triple-quadropole mass spectrometer (Applied 
Biosystems, Foster City, CA).   
 
Mobile phases of 0.1% formic acid in water and 0.1% formic acid in methanol 
were used with a 5-95% methanol linear gradient.  The column used was a 
Phenomenex Synergy Polar RP, 30 X 2 mm, with 5 µm particle size phenyl-ether 
linked stationary phase.  A flow rate of 0.8 mL/min and injection volume of 15 µL 
were utilized.  Samples were ionized using APCI and ions were monitored at the 
following transitions: 472/436 for terfenadine, 503/466 for fexofenadine, 268/143 
for azacyclonol, 477/266 for loperamide, 463/252 for monodemethyl loperamide, 
and 449/238 for didemethyl loperamide.  Standards were available for each of 
the metabolites, allowing accurate quantification.   Cetirizine was used as an 
internal standard. 
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D. RESULTS 
 
The first study was conducted in order to determine whether absorptive 
permeation of terfenadine across Caco-2 cell monolayers produces more 
metabolites than that in the secretory direction.  At a dose of 20 µM terfenadine, 
the absorptive metabolic rate was approximately 60% higher than the secretory 
rate.  In contrast, at a higher dosing concentration, the effect seemed to be 
saturable: absorptive and secretory metabolic rates were more similar (Figure 
IV.1). 
 
A similar study was carried out for loperamide at a dose of 20 µM.  As shown 
in Figure IV.2, there was a marked difference between A-to-B and B-to-A 
metabolism for loperamide.  More importantly, this effect was not diminished by 
pretreatment of the cells with P-gp inhibitor GW918; the absorptive metabolic 
rate remained about 6-fold higher than the secretory rate. 
 
The next set of experiments used fresh intestinal tissue from mice in order to 
determine whether the effect would be seen in a more physiological system.  
Indeed, for a 10 µM dose of terfenadine, a 4-fold higher metabolic rate was 
observed in the absorptive direction (Figure IV.3).  At a higher dose (50 µM), the 
effect was again diminished but the rates were still significantly different.  The 
same results were obtained for loperamide in normal mouse tissue.  Even at a 
dose of 150 µM loperamide, the effect was less but was still apparent (Figure 
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IV.4).  Finally, a P-gp deficient mouse intestine was used to determine whether 
the effect is mediated solely by P-gp.  At a 5 µM dose of terfenadine, the 
metabolic rate in the absorptive direction remained about 2-fold higher than that 
in the secretory direction. 
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E. DISCUSSION 
When absorptive metabolism of dual CYP3A/P-gp substrates was shown to 
be higher than secretory metabolism, it was logically deduced that P-gp may be 
responsible.  This result was confirmed for loperamide and terfenadine in this 
work, in both the Caco-2 cell model and in fresh mouse intestine.  The effect 
appeared to be saturable, which implies that the cause is not a nonspecific 
mechanism, such as binding.  However, in the Caco-2 cell model, the effect was 
not diminished by complete inhibition of P-gp, implying that there are other 
mechanisms at play besides P-gp efflux. 
 
Similarly, in the mouse model, A-to-B permeation of both terfenadine and 
loperamide produced more metabolites than B-to-A permeation.  The effect was 
somewhat diminished at higher dosing concentrations, again implying saturability 
of the mechanism involved.  When the experiment was performed using P-gp-
deficient mouse intestine, absorptive metabolic rate was still 2-fold higher than 
the secretory rate.  Since the difference between the metabolic rates was 
decreased compared to the wild-type mouse, P-gp may be partially responsible 
for this interaction.  However, there must still be some other process at play that 
either increases substrate concentration at the enzyme site when the drug is 
dosed on the apical side, or decreases effective concentrations when the drug is 
dosed basolaterally. 
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Another experiment that would help to clarify this issue would be to measure 
the metabolism of a CYP3A substrate that is not affected by P-gp in the 
absorptive and secretory directions.  This would help to further determine 
whether P-gp has any involvement in this interaction. 
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F. CONCLUSIONS 
In summary, in the Caco-2 cell system, absorptive metabolism produces more 
metabolites than secretory metabolism for dual CYP3A/P-gp substrates.  Some 
authors have postulated that the enhancement of metabolism observed in the A-
to-B direction is due to drug efflux by P-glycoprotein (P-gp).  However, since this 
inequality was not abolished by chemical P-gp inhibition or by genetic P-gp 
knockout, P-gp is not likely to be responsible.  Instead, another mechanism such 
as functional coupling of CYP3A to the apical membrane, resulting in better 
access of the drug to the enzyme from the apical direction, may be responsible. 
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Figure IV.1. Apical to Basolateral (A-to-B) versus 
Basolateral to Apical (B-to-A) metabolism of 
terfenadine in Caco-2 cell monolayers.  Mean of 3 ± 
SD.  A significant difference was observed between 
metabolism in the A-to-B and B-to-A directions at the 
20 µM dose level only (p<0.05, student’s t-test). 
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Figure IV.2. Apical to Basolateral (A-to-B) versus 
Basolateral to Apical (B-to-A) metabolism of 
terfenadine in Caco-2 cell monolayers, in the presence 
and absence of 1 µM P-gp inhibitor GW918.  Mean of 
3 ± SD.  A significant difference was observed 
between metabolism in the A-to-B and B-to-A 
directions in both treated and untreated groups; a 
significant difference between treated and untreated 
groups was observed in the A-to-B direction only 
(p<0.05, student’s t-test). 
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Figure IV.3. Apical to Basolateral (A-to-B) versus Basolateral 
to Apical (B-to-A) metabolism of terfenadine in P-gp-
competent mouse intestine.  Mean of 3 ± SD.  A significant 
difference was observed between metabolism in the A-to-B 
and B-to-A directions at both dose levels (p<0.05, student’s t-
test). 
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Figure IV.4. Apical to Basolateral (A-to-B) versus 
Basolateral to Apical (B-to-A) metabolism of loperamide 
in P-gp-competent mouse intestine.  Mean of 3 ± SD.  A 
significant difference was observed between 
metabolism in the A-to-B and B-to-A directions at the 20 
µM dose level only (p<0.05, student’s t-test). 
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Figure IV.5. Apical to Basolateral (A-to-B) versus 
Basolateral to Apical (B-to-A) metabolism of terfenadine (5 
µM dose) in P-gp-deficient mouse intestine.  Mean of 3 ± 
SD.  A significant difference was observed between 
metabolism in the A-to-B and B-to-A directions (p<0.05, 
student’s t-test). 
 
